Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4965—Non-condensed pyrazines
  • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
  • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
  • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
  • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
  • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
  • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
  • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• Components of the RAS/RAF/MEK/ERK (MAPK) pathway represent opportunities for the treatment of abnormal cell growth, e.g., cancer.
• Selective inhibitors of certain components of the RAS/RAF/MEK/ERK pathway such as RAS, RAF, MEK and ERK, are useful in the treatment of abnormal cell growth, in particular cancer, in mammals.
• Simultaneous targeting of multiple nodes in the MAPK pathway may improve response (e.g., antitumor response, e.g., in depth and/or duration) compared to blocking a single node in the pathway.
• the efficacy of MAPK pathway blockade may be circumvented through activation of resistance pathways, and thus cotargeting the MAPK pathway and relevant parallel pathways may be needed.
• Simultaneous targeting of multiple nodes in the MAPK pathway may improve response (e.g., antitumor response, e.g., in depth and/or duration).
• combinations e.g., combinations of compounds as described herein, e.g., a SHP2 inhibitor, a S0S1 inhibitor, an ERK1/2 inhibitor, a CDK4/6 inhibitor, an AKT inhibitor, an mTOR inhibitor, a pan-HER inhibitor, or an EGFR inhibitor in combination with a MEK inhibitor or a dual RAF/MEK inhibitor
• a SHP2 inhibitor e.g., a SHP2 inhibitor
• a S0S1 inhibitor e.g., an ERK1/2 inhibitor, a CDK4/6 inhibitor, an AKT inhibitor, an mTOR inhibitor, a pan-HER inhibitor, or an EGFR inhibitor
• an EGFR inhibitor in combination with a MEK inhibitor or a dual RAF/MEK inhibitor
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a SHP2 inhibitor in combination with a MEK inhibitor, thereby treating the subject.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a SHP2 inhibitor in combination with a dual RAF/MEK inhibitor, thereby treating the subject.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a S0S1 inhibitor in combination with a MEK inhibitor, thereby treating the subject.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a S0S1 inhibitor in combination with a dual RAF/MEK inhibitor, thereby treating the subject.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a ERK1/2 inhibitor in combination with a MEK inhibitor, thereby treating the subject.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a ERK1/2 inhibitor in combination with a dual RAF/MEK inhibitor, thereby treating the subject.
• provided herein is a method of treating a cancer in a subject in need thereof, the method comprising administering to the subject a CDK4/6 inhibitor in combination with a MEK inhibitor, thereby treating the subject.
• provided herein is a method of treating a cancer in a subject in need thereof, the method comprising administering to the subject a CDK4/6 inhibitor in combination with a dual RAF/MEK inhibitor, thereby treating the subject.
• provided herein is a method of treating a cancer in a subject in need thereof, the method comprising administering to the subject an AKT inhibitor in combination with a MEK inhibitor, thereby treating the subject.
• a method of treating a cancer in a subject in need thereof the method comprising administering to the subject an AKT inhibitor in combination with a dual RAF/MEK inhibitor, thereby treating the subject.
• provided herein is a method of treating a cancer in a subject in need thereof, the method comprising administering to the subject an mTOR inhibitor in combination with a MEK inhibitor, thereby treating the subject.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject an mTOR inhibitor in combination with a dual RAF/MEK inhibitor, thereby treating the subject.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a pan-HER inhibitor in combination with a MEK inhibitor, thereby treating the subject.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a pan-HER inhibitor in combination with a dual RAF/MEK inhibitor, thereby treating the subject.
• provided herein is a method of treating a cancer in a subject in need thereof, the method comprising administering to the subject a EGFR inhibitor in combination with a MEK inhibitor, thereby treating the subject.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a EGFR inhibitor in combination with a dual RAF/MEK inhibitor, thereby treating the subject.
• the dual RAF/MEK inhibitor is a compound of formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the dual RAF/MEK inhibitor is a potassium salt of the compound of formula (I). Other pharmaceutically acceptable salts of the compound of formula (I) are contemplated herein in the disclosed methods of treatment.
• FIG. 1A shows an exemplary CellTiter-Glo assay to evaluate cell viability on a 16 KRAS G12C, G12D or G12V mutant cell lines (9 NSCLC and 7 PDAC) grown in 3D conditions in a 7-day assay for VS-6766, RMS-4550, and TNO155.
• FIG. IB shows IC50 for VS-6766, TNO155, and RMC-4550.
• FIG. 2A shows an exemplary CTG proliferation assay with VS-6766 and TNO155 in H2122 cells.
• FIG. 2B shows an exemplary synergy analysis with VS-6766 and TNO155 in H2122 cells.
• FIG. 2C shows exemplary waterfall graphs summarizing the combination synergy results for VS-6766 + TNO155 in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 3A shows an exemplary waterfall graph summarizing the combination synergy results for VS-6766 + TNO155 in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 3B shows exemplary data on the combination of VS-6766 and TNO155 showing an increase in anti-tumor responses in H2122 cells.
• FIG. 4A shows an exemplary waterfall graph summarizing the combination synergy results for VS-6766 + RMC-4550 in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 4B shows exemplary data on the combination of VS-6766 and RMC-4550 showing an increase in anti-tumor responses in H2122 cells.
• FIG. 5A shows exemplary changes in tumor volumes in H2122 tumor bearing mice treated with VS-6766 (0.3 mg/kg QD) +/- RMC-4550 (10 mg/kg QD).
• FIG. 5B shows exemplary changes in tumor volumes in H2122 tumor bearing mice treated with VS-6766 (0.3 mg/kg QD) +/- TNO155 (15 mg/kg BID).
• FIG. 6A shows an exemplary' CellTiter-Glo assay to evaluate cell viability on a 16 KRAS G12C, G12D or G12V mutant cell lines (9 NSCLC and 7 PDAC) grown in 3D conditions in a 7-day assay for VS-6766 and BI3406.
• FIG. 6B shows IC50 for VS-6766 and BI3406.
• FIG. 7A shows an exemplary CTG proliferation assay with VS-6766 and BI3406 in H2122 cells.
• FIG. 7B shows an exemplary synergy analysis with VS-6766 and BI3406 in H2122 cells.
• FIG. 7C shows exemplary waterfall graphs summarizing the combination synergy results for VS-6766 + BI3406 in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 8A shows an exemplary waterfall graph summarizing the combination synergy results for VS-6766 + BI3406 in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 8B shows exemplary data on the combination of VS-6766 with BI3406 showing an increase in anti-tumor responses in H2122 cells.
• FIG. 9 shows exemplary changes in tumor volumes in H2122 tumor bearing mice treated with VS-6766 (0.3 mg/kg QD) +/- BL3406 (50 mg/kg BID).
• FIG. 10 A shows an exemplary CellTiter-Glo assay to evaluate cell viability on a 16 KRAS G12C, G12D or G12V mutant cell lines (9 NSCLC and 7 PDAC) grown in 3D conditions in a 7-day assay for VS-6766 and LY-3214996.
• FIG. 10B shows IC50 for VS-6766 and LY-3214996.
• FIG. 11A shows an exemplar ⁇ ' CTG proliferation assay with VS-6766 and LY-3214996 in H2122 cells.
• FIG. 11B shows an exemplary synergy analysis with VS-6766 and LY-3214996 in H2122 cells.
• FIG. 11C shows exemplary waterfall graphs summarizing the combination synergy results for VS-6766 + LY-3214996 in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 12A shows an exemplary waterfall graph summarizing the combination synergy results for VS-6766 + LY-3214996 in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 12B shows exemplary data on the combination of VS-6766 with LY-3214996 showing an increase in anti-tumor responses in H2122 cells.
• FIG. 13 shows exemplary changes in tumor volumes in H2122 tumor bearing mice treated with VS-6766 (0.3 mg/kg QD) +/- LY-3214996 (60 mg/kg QD).
• FIG. 14A shows an exemplary CellTiter-Glo assay to evaluate cell viability on a 16 KRAS G12C, G12D or G12V mutant cell lines (9 NSCLC and 7 PDAC) grown in 3D conditions in a 7-day assay for VS-6766, palbociclib and abemaciclib.
• FIG. 14B shows IC50 for VSVS-6766, palbociclib and abemaciclib.
• FIG. 15A shows an exemplar ⁇ ' CTG proliferation assay with VS-6766 and palbociclib in A427 cells.
• FIG. 15B shows an exemplary synergy analysis with VS-6766 and palbociclib in A427 cells.
• FIG. 15C shows exemplary waterfall graphs summarizing the combination synergy results for VS-6766 + palbociclib in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 16A shows an exemplar ⁇ ' graph summarizing the combination synergy results for VS- 6766 + palbociclib in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 16B shows exemplary data on the combination of VS-6766 with palbociclib showing an increase in anti-tumor responses in A427 cells.
• FIG. 17A shows an exemplar ⁇ ' graph summarizing the combination synergy results for VS- 6766 + abemaciclib in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 17B shows exemplary data on the combination of VS-6766 with abemaciclib showing an increase in anti-tumor responses in A427 cells.
• FIG. 18 shows exemplary changes in tumor volumes in H2122 tumor bearing mice treated with VS-6766 (0.3 mg/kg QD) +/- abemaciclib (25 mg/kg QD).
• FIG. 19A shows exemplary Bliss, Loewe, HSA and ZIP synergy analysis for VS-6766 + abemaciclib in ER+ breast cancer cells.
• FIG. 19B shows exemplary Bliss synergy scores in MCF7 ER+ breast cancer cells for VS- 6766 + abemaciclib.
• FIG. 19C shows exemplary Bliss synergy scores in ZR-75-1 ER+ breast cancer cells for for VS-6766 + abemaciclib.
• FIG. 20A shows an exemplar ⁇ ' CellTiter-Glo assay to evaluate cell viability on a 16 KRAS G12C, G12D or G12V mutant cell lines (9 NSCLC and 7 PDAC) grown in 3D conditions in a 7-day assay for VS-6766, ipatasertib, M2698 and everolimus.
• FIG. 20B shows IC50 for VSVS-6766, ipatasertib, M2698 and everolimus.
• FIG. 21A shows an exemplar ⁇ ' CTG proliferation assay with VS-6766 and M2698 in SW1573 cells.
• FIG. 21B shows an exemplary synergy analysis with VS-6766 and M2698 in SW1573 cells.
• FIG. 21C shows exemplary waterfall graphs summarizing the combination synergy results for VS-6766 + M2698 in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 22A shows an exemplar ⁇ ' graph summarizing the combination synergy results for VS- 6766 + ipatasertib in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 22B shows exemplary data on the combination of VS-6766 with ipatasertib showing an increase in anti-tumor responses in SW1573 cells.
• FIG. 23A shows an exemplary graph summarizing the combination synergy results for VS- 6766 + M2698 in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 23B shows exemplary data on the combination of VS-6766 with M2698 showing an increase in anti-tumor responses in SW1573 cells.
• FIG. 24A shows an exemplary graph summarizing the combination synergy results for VS- 6766 + everolimus in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 24B shows exemplary data on the combination of VS-6766 with everolimus showing an increase in anti -tumor responses in SW1573 cells.
• FIG. 25A shows exemplary CellTiter-Glo assay to evaluate cell viability on a 16 KRAS G12C, G12D or G12V mutant cell lines (9 NSCLC and 7 PDAC) grown in 3D conditions in a 7-day assay for VS-6766 and afatinib.
• FIG. 25B shows IC50 for VS-6766 and afatinib.
• FIG. 26A shows an exemplary' CTG proliferation assay with VS-6766 and afatinib in H2122.
• FIG. 26B shows an exemplary synergy analysis with VS-6766 and afatinib in H2122.
• FIG. 26C shows exemplary waterfall graphs summarizing the combination synergy results for VS-6766 + afatinib in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 27A shows an exemplary graph summarizing the combination synergy results for VS- 6766 + afatinib in a panel of KRAS mut NSCLC and PDAC cell lines.
• FIG. 27B shows exemplary data on the combination of VS-6766 with afatinib showing an increase in anti-tumor responses in H2122 cells.
• FIG. 28 shows exemplary changes in tumor volumes in H2122 tumor bearing mice treated with VS-6766 (0.3 mg/kg QD) +/- afatinib (10 mg/kg QD).
• FIG. 29 shows exemplary changes in in tumor volumes and survival in Hl 975 (L858R/T790M) tumor bearing mice treated with VS-6766 (0.3 mg/kg QD) +/- Osimertinib (2.5 mg/kg QD).
• FIG. 30 shows exemplary changes in tumor volumes and survival in H1975 osimertinib- resistant (Dell9/T790M/C797S) tumor bearing mice treated with VS-6766 (0.3 mg/kg QD) +/- Osimertinib (2.5 mg/kg QD).
• the present disclosure provides methods and combinations of compounds (e.g., combinations of compounds as described herein, e.g., a SHP2 inhibitor, a S0S1 inhibitor, an ERK1/2 inhibitor, a CDK4/6 inhibitor, an AKT inhibitor, an mTOR inhibitor, a pan-HER inhibitor, or an EGFR inhibitor in combination with a MEK inhibitor or a dual RAF/MEK inhibitor) useful for treating abnormal cell growth (e.g., cancer) in a subject in need thereof.
• compounds e.g., combinations of compounds as described herein, e.g., a SHP2 inhibitor, a S0S1 inhibitor, an ERK1/2 inhibitor, a CDK4/6 inhibitor, an AKT inhibitor, an mTOR inhibitor, a pan-HER inhibitor, or an EGFR inhibitor in combination with a MEK inhibitor or a dual RAF/MEK inhibitor
• Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and/or diastereomers.
• the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer.
• Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses.
• HPLC high pressure liquid chromatography
• a pure enantiomeric compound is substantially free from other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess).
• an “S” form of the compound is substantially free from the “R” form of the compound and is, thus, in enantiomeric excess of the “R” form.
• enantiomerically pure or “pure enantiomer” denotes that the compound comprises more than 75% by weight, more than 80% by weight, more than 85% by weight, more than 90% by weight, more than 91% by weight, more than 92% by weight, more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 98.5% by weight, more than 99% by weight, more than 99.2% by weight, more than 99.5% by weight, more than 99.6% by weight, more than 99.7% by weight, more than 99.8% by weight or more than 99.9% by weight, of the enantiomer.
• the weights are based upon total weight of all enantiomers or stereoisomers of the compound.
• an enantiomerically pure compound can be present with other active or inactive ingredients.
• a pharmaceutical composition comprising enantiomerically pure R-compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure R-compound.
• the enantiomerically pure R-compound in such compositions can, for example, comprise, at least about 95% by weight R-compound and at most about 5% by weight S-compound, by total weight of the compound.
• a pharmaceutical composition comprising enantiomerically pure S-compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure S-compound.
• the enantiomerically pure S-compound in such compositions can, for example, comprise, at least about 95% by weight S-compound and at most about 5% by weight R-compound, by total weight of the compound.
• the active ingredient can be formulated with little or no excipient or carrier.
• Compound described herein may also comprise one or more isotopic substitutions.
• H may be in any isotopic form, including 1 H, 2 H (D or deuterium), and 3 H (T or tritium);
• C may be in any isotopic form, including 12 C, 13 C, and 14 C;
• O may be in any isotopic form, including 16 O and 18 O;
• F may be in any isotopic form, including 18 F and 19 F; and the like.
• halogen atom means any one of the radio stable atoms of column 7 of the Periodic Table of the Elements, e.g., fluorine, chlorine, bromine, or iodine, with fluorine and chlorine being preferred.
• esters refers to a chemical moiety with formula -(R) n - COOR’, where R and R’ are independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), and where n is 0 or 1.
• amide refers to a chemical moiety with formula -(R) n - C(O)NHR’ or -(R) n -NHC(O)R’, where R and R’ are independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), and where n is 0 or 1.
• An amide may be an amino acid or a peptide molecule attached to a molecule of the present invention, thereby forming a prodrug.
• Any amine, hydroxyl, or carboxyl side chain on the compounds disclosed herein can be esterified or amidified.
• the procedures and specific groups to be used to achieve this end are known to those of skill in the art and can readily be found in reference sources such as Greene and Wuts, Protective Groups in Organic Synthesis, 3 rd Ed., John Wiley & Sons, New York, NY, 1999, which is incorporated herein in its entirety.
• aromatic refers to an aromatic group which has at least one ring having a conjugated pi electron system and includes both carbocyclic aryl (e.g., phenyl) and heterocyclic aryl groups (e.g., pyridine).
• carbocyclic aryl e.g., phenyl
• heterocyclic aryl groups e.g., pyridine
• the term includes monocyclic or fused- ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups.
• carbocyclic refers to a compound which contains one or more covalently closed ring structures, and that the atoms forming the backbone of the ring are all carbon atoms. The term thus distinguishes carbocyclic from heterocyclic rings in which the ring backbone contains at least one atom which is different from carbon.
• hetero aromatic refers to an aromatic group which contains at least one heterocyclic ring.
• Ca to Cb in which “a” and “b” are integers refer to the number of carbon atoms in an alkyl, alkenyl or alkynyl group, or the number of carbon atoms in the ring of a cycloalkyl, aryl, heteroaryl or heterocyclyl group. That is, the alkyl, alkenyl, alkynyl, ring of the cycloalkyl, ring of the aryl, ring of the heteroaryl or ring of the heterocyclyl can contain from “a” to “b”, inclusive, carbon atoms.
• a “Cl to C 4 alkyl” group or a “C 1 -C 4 alkyl” group refers to all alkyl groups having from 1 to 4 carbons, that is, CH 3 -, CH 3 CH 2 -, CH 3 CH 2 CH 2 -, (CH 3 ) 2 CH-, CH 3 CH 2 CH 2 CH 2 -, CH 3 CH 2 CH(CH 3 )- and (CH 3 ) 3 C-.
• cycloalkyl group may contain from “a” to “b”, inclusive, total atoms, such as a C 3 -C 8 cycloalkyl group, 3 to 8 carbon atoms in the ring(s).
• a “4 to 7 membered heterocyclyl” group refers to all heterocyclyl groups with 4 to 7 total ring atoms, for example, azetidine, oxetane, oxazoline, pyrrolidine, piperidine, piperazine, morpholine, and the like.
• C 1 -C 6 includes C 1 , C 2 , C 3 , C 4 , C 5 and C 6 , and a range defined by any of the two preceding numbers.
• C 1 -C 6 alkyl includes C l , C 2 , C 3 , C 4 , C 5 and C 6 alkyl, C 2 -C 6 alkyl, C 1 -C 3 alkyl, etc.
• C 3 -C 8 carbocyclyl or cycloalkyl each includes hydrocarbon ring containing 3, 4, 5, 6, 7 and 8 carbon atoms, or a range defined by any of the two numbers, such as C3-C7 cycloalkyl or C5-C6 cycloalkyl.
• 3 to 10 membered heterocyclyl includes 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, or a range defined by any of the two preceding numbers, such as 4 to 6 membered or 5 to 7 membered heterocyclyl.
• alkyl refers to a straight or branched hydrocarbon chain fully saturated (no double or triple bonds) hydrocarbon group.
• the alkyl group may have 1 to 20 carbon atoms (whenever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; e.g., “1 to 20 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated).
• the alkyl group may also be a medium size alkyl having 1 to 10 carbon atoms.
• the alkyl group could also be a lower alkyl having 1 to 5 carbon atoms.
• the alkyl group of the compounds may be designated as “C1-C4 alkyl” or similar designations.
• “C1-C4 alkyl” indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl.
• Exemplary alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, and the like.
• the alkyl group may be substituted or unsubstituted.
• the substituent group(s) is(are) one or more group(s) individually and independently selected from alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, protected hydroxyl, alkoxy, aryloxy, acyl, ester, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamyl, N- carbamyl, O -thiocarb amyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N- sulfonamido, C-carboxy, protected C-car
• alkenyl refers to an alkyl group that contains in the straight or branched hydrocarbon chain one or more double bonds.
• An alkenyl group may be unsubstituted or substituted. When substituted, the substituent(s) may be selected from the same groups disclosed above with regard to alkyl group substitution.
• the alkenyl group may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term “alkenyl” where no numerical range is designated.
• the alkenyl group may also be a medium size alkenyl having 2 to 9 carbon atoms.
• the alkenyl group could also be a lower alkenyl having 2 to 4 carbon atoms.
• the alkenyl group of the compounds may be designated as “C2-C4 alkenyl” or similar designations.
• C 2 -C 4 alkenyl indicates that there are two to four carbon atoms in the alkenyl chain, i.e., the alkenyl chain is selected from the group consisting of ethenyl, propen-l-yl, propen-2-yl, propen-3-yl, buten-1- yl, buten-2-yl, buten-3-yl, buten-4-yl, 1-methyl-propen-l-yl, 2-methyl-propen-l-yl, 1-ethyl- ethen-l-yl, 2-methyl-propen-3-yl, buta-l,3-dienyl, buta-l,2,-dienyl, and buta-l,2-dien-4-yl.
• Exemplary alkenyl groups include, but are in no way limited to, ethenyl, propen
• alkynyl refers to an alkyl group that contains in the straight or branched hydrocarbon chain one or more triple bonds.
• An alkynyl group may be unsubstituted or substituted. When substituted, the substituent(s) may be selected from the same groups disclosed above with regard to alkyl group substitution.
• the alkynyl group may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term “alkynyl” where no numerical range is designated.
• the alkynyl group may also be a medium size alkynyl having 2 to 9 carbon atoms.
• the alkynyl group could also be a lower alkynyl having 2 to 4 carbon atoms.
• the alkynyl group of the compounds may be designated as “C2-C4 alkynyl” or similar designations.
• C2-C4 alkynyl indicates that there are two to four carbon atoms in the alkynyl chain, i.e., the alkynyl chain is selected from the group consisting of ethynyl, propyn-l-yl, propyn-2-yl, butyn-l-yl, butyn-3- yl, butyn-4-yl, and 2-butynyl.
• Exemplary alkynyl groups include, but are in no way limited to, ethynyl, propynyl, butynyl, pentynyl, and hexynyl, and the like.
• heteroalkyl refers to a straight or branched hydrocarbon chain containing one or more heteroatoms, that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur, in the chain backbone.
• the heteroalkyl group may have 1 to 20 carbon atoms although the present definition also covers the occurrence of the term “heteroalkyl” where no numerical range is designated.
• the heteroalkyl group may also be a medium size heteroalkyl having 1 to 9 carbon atoms.
• the heteroalkyl group could also be a lower heteroalkyl having 1 to 4 carbon atoms.
• the heteroalkyl group of the compounds may be designated as “C1-C4 heteroalkyl” or similar designations.
• the heteroalkyl group may contain one or more heteroatoms.
• C 1 -C 4 heteroalkyl indicates that there are one to four carbon atoms in the heteroalkyl chain and additionally one or more heteroatoms in the backbone of the chain.
• aryl refers to a carbocyclic (all carbon) ring or two or more fused rings (rings that share two adjacent carbon atoms) that have a fully delocalized pi -electron system.
• aryl groups include, but are not limited to, benzene, naphthalene and azulene.
• An aryl group may be substituted or unsubstituted.
• substituent group(s) that is(are) one or more group(s) independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, protected hydroxyl, alkoxy, aryloxy, acyl, ester, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, protected C-carboxy, O-carboxy, iso
• substituents on an aryl group may form a non-aromatic ring fused to the aryl group, including a cycloalkyl, cycloalkenyl, cycloalkynyl, and heterocyclyl.
• heteroaryl refers to a monocyclic or multicyclic aromatic ring system (a ring system with fully delocalized pi-electron system), one or two or more fused rings that contain(s) one or more heteroatoms, that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur.
• heteroaryl rings include, but are not limited to, furan, thiophene, phthalazine, pyrrole, oxazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, triazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine and triazine.
• a heteroaryl group may be substituted or unsubstituted.
• hydrogen atoms are replaced by substituent group(s) that is(are) one or more group(s) independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, protected hydroxyl, alkoxy, aryloxy, acyl, ester, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carbox
• substituents on a heteroayl group may form a non-aromatic ring fused to the aryl group, including a cycloalkyl, cycloalkenyl, cycloalkynyl, and heterocyclyl.
• an “aralkyl” or “arylalkyl” refers to an aryl group connected, as a substituent, via an alkylene group.
• the alkylene and aryl group of an aralkyl may be substituted or unsubstituted. Examples include but are not limited to benzyl, substituted benzyl, 2-phenylethyl, 3 -phenylpropyl, and naphtylalkyl.
• the alkylene group is a lower alkylene group.
• a “heteroaralkyl” or “heteroarylalkyl” is heteroaryl group connected, as a substituent, via an alkylene group.
• the alkylene and heteroaryl group of heteroaralkyl may be substituted or unsubstituted. Examples include but are not limited to 2- thienylmethyl, 3 -thienylmethyl, furylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazollylalkyl, and imidazolylalkyl, and their substituted as well as benzo-fused analogs.
• the alkylene group is a lower alkylene group.
• alkylene refers to a branched, or straight chain fully saturated diradical chemical group containing only carbon and hydrogen that is attached to the rest of the molecule via two points of attachment (i.e., an alkanediyl).
• the alkylene group may have 1 to 20 carbon atoms, although the present definition also covers the occurrence of the term alkylene where no numerical range is designated.
• the alkylene group may also be a medium size alkylene having 1 to 9 carbon atoms.
• the alkylene group could also be a lower alkylene having 1 to 4 carbon atoms.
• the alkylene group may be designated as “C1-C4 alkylene” or similar designations.
• C1-C4 alkylene indicates that there are one to four carbon atoms in the alkylene chain, i.e., the alkylene chain is selected from the group consisting of methylene, ethylene, ethan- 1,1 -diyl, propylene, propan- 1,1-diyl, propan-2, 2- diyl, 1 -methyl-ethylene, butylene, butan- 1,1-diyl, butan-2,2-diyl, 2-methyl- propan- 1,1- diyl, 1 -methyl-propylene, 2-methyl-propylene, 1,1 -dimethyl-ethylene, 1,2- dimethylethylene, and 1-ethyl-ethylene.
• alkenylene refers to a straight or branched chain di radical chemical group containing only carbon and hydrogen and containing at least one carbon-carbon double bond that is attached to the rest of the molecule via two points of attachment.
• the alkenylene group may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term alkenylene where no numerical range is designated.
• the alkenylene group may also be a medium size alkenylene having 2 to 9 carbon atoms.
• the alkenylene group could also be a lower alkenylene having 2 to 4 carbon atoms.
• the alkenylene group may be designated as “C2-C4 alkenylene” or similar designations.
• C2 alkenylene indicates that there are two to four carbon atoms in the alkenylene chain, i.e., the alkenylene chain is selected from the group consisting of ethenylene, ethen- 1,1 -diyl, propenylene, propen- 1,1 -diyl, prop-2-en- 1,1 -diyl, 1 -methyl- ethenylene, but-l-enylene, but-
• arylalkylidene refers to an alkylidene group in which either R’ and R’ ’ is an aryl group. An alkylidene group may be substituted or unsubstituted.
• alkoxy refers to the formula -OR wherein R is an alkyl is defined as above, e.g. methoxy, ethoxy, n-propoxy, 1 -methylethoxy (isopropoxy), n- butoxy, iso-butoxy, sec-butoxy, tert-butoxy, amoxy, tert-amoxy and the like.
• An alkoxy may be substituted or unsubstituted.
• alkylthio refers to the formula -SR wherein R is an alkyl is defined as above, e.g. methylmercapto, ethylmercapto, n-propylmercapto, 1- methylethylmercapto (isopropylmercapto), n-butylmercapto, iso-butylmercapto, sec- butylmercapto, tertbutylmercapto, and the like.
• An alkylthio may be substituted or unsubstituted.
• aryloxy and arylthio refers to RO- and RS-, respectively, in which R is an aryl, such as but not limited to phenyl. Both an aryloxyl and arylthio may be substituted or unsubstituted.
• R is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 carbocyclyl, aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
• Non-limiting examples include formyl, acetyl, propanoyl, benzoyl, and acryl.
• cycloalkyl refers to a completely saturated (no double bonds) mono- or multi- cyclic hydrocarbon ring system. When composed of two or more rings, the rings may be joined together in a fused, bridged or spiro-connected fashion. Cycloalkyl groups may range from C3 to CIO, in other embodiments it may range from C3 to C6. A cycloalkyl group may be unsubstituted or substituted. Exemplary cycloalkyl groups include, but are in no way limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
• the substituent(s) may be an alkyl or selected from those indicated above with regard to substitution of an alkyl group unless otherwise indicated.
• substituents on a cycloalkyl group may form an aromatic ring fused to the cycloalkyl group, including an aryl and a heteroaryl.
• cycloalkenyl refers to a cycloalkyl group that contains one or more double bonds in the ring although, if there is more than one, they cannot form a fully delocalized pi-electron system in the ring (otherwise the group would be “aryl,” as defined herein). When composed of two or more rings, the rings may be connected together in a fused, bridged or spiro-connected fashion.
• a cycloalkenyl group may be unsubstituted or substituted. When substituted, the substituent(s) may be an alkyl or selected from the groups disclosed above with regard to alkyl group substitution unless otherwise indicated. When substituted, substituents on a cycloalkenyl group may form an aromatic ring fused to the cycloalkenyl group, including an aryl and a heteroaryl.
• cycloalkynyl refers to a cycloalkyl group that contains one or more triple bonds in the ring. When composed of two or more rings, the rings may be joined together in a fused, bridged or spiro-connected fashion.
• a cycloalkynyl group may be unsubstituted or substituted. When substituted, the substituent(s) may be an alkyl or selected from the groups disclosed above with regard to alkyl group substitution unless otherwise indicated. When substituted, substituents on a cycloalkynyl group may form an aromatic ring fused to the cycloalkynyl group, including an aryl and a heteroaryl.
• heteroalicyclic or “heteroalicyclyl” refers to a stable 3- to 18 membered ring which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
• heteroalicyclic or “heteroalicyclyl” may be monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may be joined together in a fused, bridged or spiro-connected fashion; and the nitrogen, carbon and sulfur atoms in the “heteroalicyclic” or “heteroalicyclyl” may be optionally oxidized; the nitrogen may be optionally quatemized; and the rings may also contain one or more double bonds provided that they do not form a fully delocalized pi-electron system throughout all the rings.
• Heteroalicyclyl groups may be unsubstituted or substituted.
• the substituent(s) may be one or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, protected hydroxyl, alkoxy, aryloxy, acyl, ester, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyan
• heteroalicyclic or “heteroalicyclyl” include but are not limited to, azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, morpholinyl, oxiranyl, piperidinyl A-oxide, piperidinyl, piperazinyl, pyrrolidinyl, 4-piperidonyl, pyrazolidinyl, 2-oxopyrrolidinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, and thiamorpholinyl sulfone.
• substituents on a heteroalicyclyl group may form an aromatic ring fused to the heteroalicyclyl group, including an aryl and a heteroaryl.
• (cycloalkenyl)alkyl refers to a cycloalkenyl group connected, as a substituent, via an alkylene group.
• the alkylene and cycloalkenyl of a (cycloalkenyl)alkyl may be substituted or unsubstituted.
• the alkylene group is a lower alkylene group.
• (cycloalkynyl)alkyl to a cycloalkynyl group connected, as a substituent, via an alkylene group.
• the alkylene and cycloalkynyl of a (cycloalkynyl)alkyl may be substituted or unsubstituted.
• the alkylene group is a lower alkylene group.
• R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as defined herein.
• An O-carboxy may be substituted or unsubstituted.
• a C-carboxy may be substituted or unsubstituted.
• trihalomethanesulfonyl refers to an “X3CSO2-“ group wherein X is a halogen.
• cyano refers to a “-CN” group.
• cyanato refers to an “-OCN” group.
• isocyanato refers to a “-NCO” group.
• thiocyanato refers to a “-SCN” group.
• isothiocyanato refers to an “-NCS” group.
• sulfonyl refers to an “-SO2R” group in which R can be the same as defined with respect to O-carboxy. A sulfonyl may be substituted or unsubstituted.
• S-sulfonamido refers to a “-SO2NRARB” group in which RA and RB can be the same as defined with respect to O-carboxy.
• An S-sulfonamido may be substituted or unsubstituted.
• N-sulfonamido refers to a “-SO2N(RA)(RB)” group in which RA and RB can be the same as defined with respect to O-carboxy.
• a sulfonyl may be substituted or unsubstituted.
• trihalomethanesulfonamido refers to an “X3CSO2N(R)-“ group with X as halogen and R can be the same as defined with respect to O-carboxy.
• a trihalomethanesulfonamido may be substituted or unsubstituted.
• An O-carbamyl may be substituted or unsubstituted.
• An N-carbamyl may be substituted or unsubstituted.
• An O-thiocarbamyl may be substituted or unsubstituted.
• An N-thiocarbamyl may be substituted or unsubstituted.
• a C-amido may be substituted or unsubstituted.
• An N-amido may be substituted or unsubstituted.
• amino refers to a “-NRARB” group in which RA and RB are each independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 carbocyclyl, C6-C10 aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
• aminoalkyl refers to an amino group connected via an alkylene group.
• An ester may be substituted or unsubstituted.
• lower aminoalkyl refers to an amino group connected via a lower alkylene group.
• a lower aminoalkyl may be substituted or unsubstituted.
• lower alkoxyalkyl refers to an alkoxy group connected via a lower alkylene group.
• a lower alkoxyalkyl may be substituted or unsubstituted.
• perhaloalkyl refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms.
• carbocyclyl refers to a non-aromatic cyclic ring or ring system containing only carbon atoms in the ring system backbone.
• carbocyclyl is a ring system, two or more rings may be joined together in a fused, bridged or spiro-connected fashion.
• Carbocyclyls may have any degree of saturation provided that at least one ring in a ring system is not aromatic.
• carbocyclyls include cycloalkyls, cycloalkenyls, and cycloalkynyls.
• the carbocyclyl group may have 3 to 20 carbon atoms, although the present definition also covers the occurrence of the term “carbocyclyl” where no numerical range is designated.
• the carbocyclyl group may also be a medium size carbocyclyl having 3 to 10 carbon atoms.
• the carbocyclyl group could also be a carbocyclyl having 3 to 6 carbon atoms.
• the carbocyclyl group may be designated as “C3-C6 carbocyclyl” or similar designations.
• carbocyclyl rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,3 -dihydro-indene, bicycle[2.2.2]octanyl, adamantyl, and spiro[4.4]nonanyl.
• (cycloalkyl)alkyl refers to a cycloalkyl group connected, as a substituent, via an alkylene group.
• the alkylene and cycloalkyl of a (cycloalkyl)alkyl may be substituted or unsubstituted.
• Examples include but are not limited cyclopropylmethyl, cyclobutylmethyl, cyclopropylethyl, cyclopropylbutyl, cyclobutylethyl, cyclopropylisopropyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cycloheptylmethyl, and the like.
• the alkylene group is a lower alkylene group.
• cycloalkyl refers to a fully saturated carbocyclyl ring or ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
• cycloalkenyl means a carbocyclyl ring or ring system having at least one double bond, wherein no ring in the ring system is aromatic. An example is cyclohexenyl.
• heterocyclyl refers to three-, four-, five-, six-, seven-, and eight- or more membered rings wherein carbon atoms together with from 1 to 3 heteroatoms constitute said ring.
• a heterocyclyl can optionally contain one or more unsaturated bonds situated in such a way, however, that an aromatic pi-electron system does not arise.
• the heteroatoms are independently selected from oxygen, sulfur, and nitrogen.
• a heterocyclyl can further contain one or more carbonyl or thiocarbonyl functionalities, so as to make the definition include oxo- systems and thio- systems such as lactams, lactones, cyclic imides, cyclic thioimides, cyclic carbamates, and the like.
• a “heterocyclyl” can refer to a nonaromatic cyclic ring or ring system containing at least one heteroatom in the ring backbone. Heterocyclyls may be joined together in a fused, bridged or spiro-connected fashion. Heterocyclyls may have any degree of saturation provided that at least one ring in the ring system is not aromatic.
• the heteroatom(s) may be present in either a non-aromatic or aromatic ring in the ring system.
• the heterocyclyl group may have 3 to 20 ring members (i.e., the number of atoms making up the ring backbone, including carbon atoms and heteroatoms), although the present definition also covers the occurrence of the term “heterocyclyl” where no numerical range is designated.
• the heterocyclyl group may also be a medium size heterocyclyl having 3 to 10 ring members.
• the heterocyclyl group could also be a heterocyclyl having 3 to 6 ring members.
• the heterocyclyl group may be designated as “3-6 membered heterocyclyl” or similar designations.
• the heteroatom(s) are selected from one up to three of O, N or S, and in preferred five membered monocyclic heterocyclyls, the heteroatom(s) are selected from one or two heteroatoms selected from O, N, or S.
• heterocyclyl rings include, but are not limited to, azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, imidazolidinyl, morpholinyl, oxiranyl, oxepanyl, thiepanyl, piperidinyl, piperazinyl, dioxopiperazinyl, pyrrolidinyl, pyrrolidonyl, pyrrolidionyl, 4-piperidonyl, pyrazolinyl, pyrazolidinyl, 1,3-dioxinyl, 1,3-dioxanyl, 1,4- dioxinyl, 1,4-dioxanyl, 1,3-oxathianyl, 1,4- oxathiinyl, 1,4-oxathianyl, 2//-l,2-oxazinyl, trioxanyl, hex
• heterocyclylalkyl refers to a heterocyclyl group connected, as a substituent, via an alkylene group. Examples include, but are not limited to, imidazolinylmethyl and indolinylethyl.
• Substituted groups are based upon or derived from the unsubstituted parent group in which there has been an exchange of one or more hydrogen atoms for another atom or group. Unless otherwise indicated, when a group is deemed to be “substituted,” the group is substituted with one or more substituents independently selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C3-C7 carbocyclyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy), C3-C7- carbocyclyl-Cl-C6-alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, Cl- C6 haloalkyl, and C1-C6 haloalkoxy
• a substituted group is substituted with one or more substituent(s) individually and independently selected from C1-C4 alkyl, amino, hydroxy, and halogen.
• radical naming conventions can include either a mono-radical or a di-radical, depending on the context. For example, where a substituent requires two points of attachment to the rest of the molecule, it is understood that the substituent is a di-radical.
• a substituent identified as alkyl that requires two points of attachment includes di-radicals such as -CH2-, -CH2CH2-, -CH2CH(CH3)CH2-, and the like.
• Other radical naming conventions clearly indicate that the radical is a di-radical such as “alkylene” or “alkenylene.”
• substituent is a group that may be substituted with one or more group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxyl, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N- thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, and amino,
• “About” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given value or range of values.
• pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
• Pharmaceutically acceptable salts are well known in the art. For example, Berge et al., describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66: 1-19.
• Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
• Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
• inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
• organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
• salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, di gluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy- ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pec
• Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (Ci ⁇ alkyl)4 salts.
• Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
• Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.
• pharmaceutically acceptable carrier refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
• Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, poly
• a “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and/or a non-human animal, e.g., a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and/or dogs.
• the subject is a human.
• the subject is a non- human animal.
• the terms “human,” “patient,” and “subject” are used interchangeably herein.
• disease, disorder, and condition are used interchangeably herein.
• the terms “treat,” “treating” and “treatment” contemplate an action that occurs while a subject is suffering from the specified disease, disorder or condition, which reduces the severity of the disease, disorder or condition, or retards or slows the progression of the disease, disorder or condition (also “therapeutic treatment”).
• the “effective amount” of a compound refers to an amount sufficient to elicit the desired biological response.
• the effective amount of a compound of the invention may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, weight, health, and condition of the subject.
• a “therapeutically effective amount” of a compound is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder or condition, or to delay or minimize one or more symptoms associated with the disease, disorder or condition.
• a therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the disease, disorder or condition.
• the term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.
• prophylactic treatment contemplates an action that occurs before a subject begins to suffer from the specified disease, disorder or condition.
• a “prophylactically effective amount” of a compound is an amount sufficient to prevent a disease, disorder or condition, or one or more symptoms associated with the disease, disorder or condition, or prevent its recurrence.
• a prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the disease, disorder or condition.
• the term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
• oral dosage form refers to a composition or medium used to administer an agent to a subject.
• oral dosage form is intended to cover any substance which is administered to a subject and is absorbed across a membrane, e.g., a mucosal membrane, of the gastrointestinal tract, including, e.g., the mouth, esophagus, stomach, small intestine, large intestine, and colon.
• oral dosage form covers a solution which is administered through a feeding tube into the stomach.
• one cycle is four weeks (e.g., administering the drug for three weeks and then not administering the drug for one week).
• a "KRAS mutation” is a mutation of the KRAS gene (i.e., a nucleic acid mutation) or Kras protein (i.e., an amino acid mutation) that results in aberrant Kras protein function associated with increased and/or constitutive activity by favoring the active GTP -bound state of the Kras protein.
• the mutation may be at conserved sites that favor GTP binding and constitutively active Kras protein.
• the mutation is at one or more of codons 12, 13, and 16 of the KRAS gene.
• a KRAS mutation may be at codon 12 of the KRAS gene, for instance, as a single point substitution mutation at codon 12 (i.e., KRAS G12X mutation) (e.g., a KRAS G12V mutation arises from a single nucleotide change (c.35G>T) and results in an amino acid substitution of the glycine (G) at position 12 by a valine (V)).
• KRAS G12X mutations include, but are not limited to, KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C.
• a “RAF mutation” is a mutation in the RAF gene.
• a “BRAF mutation” is a mutation in the BRAF gene.
• An “ARAF mutation” is a mutation in the ARAF gene.
• a “CRAF mutation” is a mutation in the CRAF gene.
• Combinations of compounds described herein are generally useful in methods of treating abnormal cell growth such as cancer.
• a SHP2 inhibitor e.g., a S0S1 inhibitor, an ERK1/2 inhibitor, a CDK4/6 inhibitor, an AKT inhibitor, an mTOR inhibitor, a pan-HER inhibitor, or an EGFR inhibitor in combination with a MEK inhibitor or a dual RAF/MEK inhibitor
• pharmaceutical compositions thereof are generally useful in methods of treating abnormal cell growth such as cancer.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a SHP2 inhibitor in combination with a MEK inhibitor, thereby treating the subject.
• the method further comprises administering an additional agent.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a SHP2 inhibitor in combination with a dual RAF/MEK inhibitor (e.g., VS-6766), thereby treating the subject.
• the method further comprises administering an additional agent.
• the duration of response to SHP2 inhibitor may be reduced by administering to a subject in need thereof a SHP2 inhibitor in combination with a MEK inhibitor. In some embodiments, the duration of response to SHP2 inhibitor may be reduced by administering to a subject in need thereof a SHP2 inhibitor in combination with a RAF/MEK inhibitor (e.g., VS-6766). In some embodiments, the combinations as described herein may improve the depth and/or duration of the response (e.g., antitumor response) in the subject.
• a contemplated subject for the methods described herein may be identified (e.g., by screening, e.g., sequencing) as having a SHP2 mutation.
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a MEK inhibitor in combination with a SHP2 inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with a SHP2 inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• a dual RAF/MEK inhibitor e.g., VS-6766
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a S0S1 inhibitor in combination with a MEK inhibitor, thereby treating the subject.
• the method further comprises administering an additional agent.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a S0S1 inhibitor in combination with a dual RAF/MEK inhibitor (e.g., VS-6766), thereby treating the subject.
• the method further comprises administering an additional agent.
• the duration of response to S0S1 inhibitor may be reduced by administering to a subject in need thereof a S0S1 inhibitor in combination with a MEK inhibitor. In some embodiments, the duration of response to S0S1 inhibitor may be reduced by administering to a subject in need thereof a S0S1 inhibitor in combination with a RAF/MEK inhibitor (e.g., VS-6766). In some embodiments, the combinations as described herein may improve the depth and/or duration of the response (e.g., antitumor response) in the subject.
• a contemplated subject for the methods described herein may be identified (e.g., by screening, e.g., sequencing) as having a S0S1 mutation.
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a MEK inhibitor in combination with a S0S1 inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with a S0S1 inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• a dual RAF/MEK inhibitor e.g., VS-6766
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a ERK1/2 inhibitor in combination with a MEK inhibitor, thereby treating the subject.
• the method further comprises administering an additional agent.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a ERK1/2 inhibitor in combination with a dual RAF/MEK inhibitor (e.g., VS-6766), thereby treating the subject.
• the method further comprises administering an additional agent.
• the duration of response to ERK1/2 inhibitor may be reduced by administering to a subject in need thereof a ERK1/2 inhibitor in combination with a MEK inhibitor. In some embodiments, the duration of response to ERK1/2 inhibitor may be reduced by administering to a subject in need thereof a ERK1/2 inhibitor in combination with a RAF/MEK inhibitor (e.g., VS-6766). In some embodiments, the combinations as described herein may improve the depth and/or duration of the response (e.g., antitumor response) in the subject.
• a contemplated subject for the methods described herein may be identified (e.g., by screening, e.g., sequencing) as having a ERK1/2 mutation.
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a MEK inhibitor in combination with a ERK1/2 inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with a ERK1/2 inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• a dual RAF/MEK inhibitor e.g., VS-6766
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a CDK4/6 inhibitor in combination with a MEK inhibitor, thereby treating the subject.
• the method further comprises administering an additional agent.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a CDK4/6 inhibitor in combination with a dual RAF/MEK inhibitor (e.g., VS-6766) or a pharmaceutically acceptable salt thereof, thereby treating the subject.
• the method further comprises administering an additional agent.
• the duration of response to CDK4/6 inhibitor may be reduced by administering to a subject in need thereof a CDK4/6 inhibitor in combination with a MEK inhibitor. In some embodiments, the duration of response to CDK4/6 inhibitor may be reduced by administering to a subject in need thereof a CDK4/6 inhibitor in combination with a RAF/MEK inhibitor (e.g., VS-6766). In some embodiments, the combinations as described herein may improve the depth and/or duration of the response (e.g., antitumor response) in the subject.
• a contemplated subject for the methods described herein may be identified (e.g., by screening, e.g., sequencing) as having a CDK4/6 mutation.
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a MEK inhibitor in combination with a CDK4/6 inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with a CDK4/6 inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• a dual RAF/MEK inhibitor e.g., VS-6766
• a method of treating a cancer in a subject in need thereof comprising administering to the subject an AKT inhibitor in combination with a MEK inhibitor, thereby treating the subject.
• the method further comprises administering an additional agent.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject an AKT inhibitor in combination with a dual RAF/MEK inhibitor (e.g., VS-6766), thereby treating the subject.
• the method further comprises administering an additional agent.
• the duration of response to AKT inhibitor may be reduced by administering to a subject in need thereof an AKT inhibitor in combination with a MEK inhibitor. In some embodiments, the duration of response to AKT inhibitor may be reduced by administering to a subject in need thereof an AKT inhibitor in combination with a RAF/MEK inhibitor (e.g., VS-6766). In some embodiments, the combinations as described herein may improve the depth and/or duration of the response (e.g., antitumor response) in the subject.
• a RAF/MEK inhibitor e.g., VS-6766
• a contemplated subject for the methods described herein may be identified (e.g., by screening, e.g., sequencing) as having an AKT mutation.
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a MEK inhibitor in combination with an AKT inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with an AKT inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• a dual RAF/MEK inhibitor e.g., VS-6766
• a method of treating a cancer in a subject in need thereof comprising administering to the subject an mTOR inhibitor in combination with a MEK inhibitor, thereby treating the subject.
• the method further comprises administering an additional agent.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject an mTOR inhibitor in combination with a dual RAF/MEK inhibitor (e.g., VS-6766) or a pharmaceutically acceptable salt thereof, thereby treating the subject.
• the method further comprises administering an additional agent.
• the duration of response to mTOR inhibitor may be reduced by administering to a subject in need thereof an mTOR inhibitor in combination with a MEK inhibitor.
• the duration of response to mTOR inhibitor may be reduced by administering to a subject in need thereof an mTOR inhibitor in combination with a RAF/MEK inhibitor (e.g., VS-6766).
• a RAF/MEK inhibitor e.g., VS-6766
• the combinations as described herein may improve the depth and/or duration of the response (e.g., antitumor response) in the subject.
• a contemplated subject for the methods described herein may be identified (e.g., by screening, e.g., sequencing) as having an mTOR mutation.
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a MEK inhibitor in combination with an mTOR inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with an mTOR inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• a dual RAF/MEK inhibitor e.g., VS-6766
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a pan-HER inhibitor in combination with a MEK inhibitor, thereby treating the subject.
• the method further comprises administering an additional agent.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a pan-HER inhibitor in combination with a dual RAF/MEK inhibitor (e.g., VS-6766) or a pharmaceutically acceptable salt thereof, thereby treating the subject.
• the method further comprises administering an additional agent.
• the duration of response to pan-HER inhibitor may be reduced by administering to a subject in need thereof a pan-HER inhibitor in combination with a MEK inhibitor. In some embodiments, the duration of response to pan-HER inhibitor may be reduced by administering to a subject in need thereof a pan-HER inhibitor in combination with a RAF/MEK inhibitor (e.g., VS-6766). In some embodiments, the combinations as described herein may improve the depth and/or duration of the response (e.g., antitumor response) in the subject.
• a contemplated subject for the methods described herein may be identified (e.g., by screening, e.g., sequencing) as having a pan-HER mutation.
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a MEK inhibitor in combination with a pan-HER inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with a pan-HER inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• a dual RAF/MEK inhibitor e.g., VS-6766
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a EGFR inhibitor in combination with a MEK inhibitor or a pharmaceutically acceptable salt thereof, thereby treating the subject.
• the method further comprises administering an additional agent.
• a method of treating a cancer in a subject in need thereof comprising administering to the subject a EGFR inhibitor in combination with a dual RAF/MEK inhibitor (e.g., VS-6766) or a pharmaceutically acceptable salt thereof, thereby treating the subject.
• the method further comprises administering an additional agent.
• the duration of response to EGFR inhibitor may be reduced by administering to a subject in need thereof a EGFR inhibitor in combination with a MEK inhibitor. In some embodiments, the duration of response to EGFR inhibitor may be reduced by administering to a subject in need thereof a EGFR inhibitor in combination with a RAF/MEK inhibitor (e.g., VS-6766). In some embodiments, the combinations as described herein may improve the depth and/or duration of the response (e.g., antitumor response) in the subject.
• a contemplated subject for the methods described herein may be identified (e.g., by screening, e.g., sequencing) as having a EGFR alteration.
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a MEK inhibitor in combination with a EGFR inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• Methods disclosed herein also contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject a dual RAF/MEK inhibitor (e.g., VS-6766) in combination with a EGFR inhibitor, optionally with an additional agent.
• KRAS G12X mutation e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C
• a dual RAF/MEK inhibitor e.g., VS-6766
• SHP2 inhibitors include, but are not limited to:
• TNO-155 (Novartis AG) having the following structure:
• IACS-13909 having the following structure:
• JAB-3312 Jacobio Pharmaceuticals Co Ltd); RLY-1971 (Relay Therapeutics Inc); BBP-398 (Navire Pharma Inc); ERAS-601 (ERASCA); HBL2376 (HUYA Bioscience International LLC); ICP-189 (InnoCare Pharma Ltd), BR790 (Shanghai Blueray Biopharma); ETS-001 (Shanghai ETERN Biopharma); PF-07284892 (Pfizer); RX-SHP2i (Redx Pharma); SH3809 (Nanjing Sanhome Pharmaceutical); TAS-ASTX (Taiho Oncology); X-37-SHP2 (X-37); and hydrates, solvates, and pharmaceutically acceptable salts thereof.
• the SHP2 inhibitor is ERAS-601, TNO-155, SHP099, RMC- 4630, RMC-4550, IACS-13909, JAB-3068, JAB-3312, RLY-1971, BBP-398, HBL2376, or ICP-189, or a hydrate, a solvate or a pharmaceutically acceptable salt thereof.
• the SHP2 inhibitor is ERAS-601, JAB-3068, RMC-4630, TNO-155, JAB-3312, RLY-1971, BBP-398, HBL2376, ICP-189, or RMC-4550, or a hydrate, a solvate or a pharmaceutically acceptable salt thereof.
• the SHP2 inhibitor is administered at least once a week. In some embodiments, the SHP2 inhibitor is administered at least once daily. In some embodiments, the SHP2 inhibitor is administered once daily. In some embodiments, the SHP2 inhibitor is administered twice daily. In some embodiments, the SHP2 inhibitor is administered orally.
• the SHP2 inhibitor is dosed at about 0.1 mg to about 5000 mg, e.g., about 1 mg to about 3000 mg, about 1 mg to about 1000 mg, about 1 mg to about 500 mg, about 1 mg to about 100 mg, about 10 mg to about 2000 mg, e.g., about 100 mg to about 2000 mg, about 100 mg to about 1500 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 100 mg to about 200 mg, about 200 mg to about 2000 mg, about 200 mg to about 1500 mg, about 200 mg to about 1000 mg, about 200 mg to about 800 mg, about 200 mg to about 600 mg, about 200 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about 600 mg, about 600 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about 600
• the SHP2 inhibitor is dosed at about 1 mg per administration. In some embodiments, the SHP2 inhibitor is dosed at about 5 mg per administration. In some embodiments, the SHP2 inhibitor is dosed at about 10 mg per administration. In some embodiments, the SHP2 inhibitor is dosed at about 50 mg per administration. In some embodiments, the SHP2 inhibitor is dosed at about 100 mg per administration. In some embodiments, the SHP2 inhibitor is dosed at about 200 mg per administration. In some embodiments, the SHP2 inhibitor is dosed at about 300 mg per administration. In some embodiments, the SHP2 inhibitor is dosed at about 400 mg per administration. In some embodiments, the SHP2 inhibitor is dosed at about 500 mg per administration.
• the SHP2 inhibitor is dosed at about 600 mg per administration. In some embodiments, the SHP2 inhibitor is dosed at about 700 mg per administration. In some embodiments, the SHP2 inhibitor is dosed at about 800 mg per administration. In some embodiments, the SHP2 inhibitor is dosed at about 900 mg per administration. In some embodiments, the SHP2 inhibitor is dosed at about 1000 mg per administration.
• S0S1 inhibitors examples include, but are not limited to:
• RMC-5845 Revolution Medicines
• SDGR-5 Scholadium gallate LLC
• BL1701963 Boehringer Ingleheim
• BMS-SCH Scholadium-S-SCH
• SDGR5 Schotham
• hydrates, solvates, and pharmaceutically acceptable salts thereof RMC-5845 (Revolution Medicines); SDGR-5 (Schrodinger LLC); BL1701963 (Boehringer Ingleheim); BMS-SCH (Schrodinger); and SDGR5 (Schrodinger), and hydrates, solvates, and pharmaceutically acceptable salts thereof.
• the S0S1 inhibitor is BI-3406, BAY-293, RMC-5845 (Revolution Medicines), SDGR-5 (Schrodinger LLC), or BI-1701963 (Boehringer Ingleheim), or a hydrate, a solvate or a pharmaceutically acceptable salt thereof.
• the S0S1 inhibitor is SDGR-5 (Schrodinger LLC) or BL 1701963 (Boehringer Ingleheim), or a hydrate, a solvate or a pharmaceutically acceptable salt thereof.
• the S0S1 inhibitor is administered at least once a week. In some embodiments, the S0S1 inhibitor is administered at least once daily. In some embodiments, the S0S1 inhibitor is administered once daily. In some embodiments, the S0S1 inhibitor is administered twice daily. In some embodiments, the S0S1 inhibitor is administered orally.
• the S0S1 inhibitor is dosed at about 0.1 mg to about 5000 mg, e.g., about 1 mg to about 3000 mg, about 1 mg to about 1000 mg, about 1 mg to about 500 mg, about 1 mg to about 100 mg, about 10 mg to about 2000 mg, e.g., about 100 mg to about 2000 mg, about 100 mg to about 1500 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 100 mg to about 200 mg, about 200 mg to about 2000 mg, about 200 mg to about 1500 mg, about 200 mg to about 1000 mg, about 200 mg to about 800 mg, about 200 mg to about 600 mg, about 200 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about 600 mg, about 600 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about
• the SOS1 inhibitor is dosed at about 1 mg per administration. In some embodiments, the SOS1 inhibitor is dosed at about 5 mg per administration. In some embodiments, the SOS1 inhibitor is dosed at about 10 mg per administration. In some embodiments, the SOS1 inhibitor is dosed at about 50 mg per administration. In some embodiments, the SOS1 inhibitor is dosed at about 100 mg per administration. In some embodiments, the SOS1 inhibitor is dosed at about 200 mg per administration. In some embodiments, the SOS1 inhibitor is dosed at about 300 mg per administration. In some embodiments, the SOS1 inhibitor is dosed at about 400 mg per administration. In some embodiments, the SOS1 inhibitor is dosed at about 500 mg per administration.
• the S0S1 inhibitor is dosed at about 600 mg per administration. In some embodiments, the S0S1 inhibitor is dosed at about 700 mg per administration. In some embodiments, the S0S1 inhibitor is dosed at about 800 mg per administration. In some embodiments, the S0S1 inhibitor is dosed at about 900 mg per administration. In some embodiments, the S0S1 inhibitor is dosed at about 1000 mg per administration.
• ERK 1/2 inhibitors include, but are not limited to:
• ASTX-029 (Astex Pharmaceuticals), having the following structure:
• LY-3214996 (Eli Lilly and Co), having the following structure: ravoxertinib, having the structure:
• BPI-27336 (Betta Pharmaceuticals Co Ltd); JSI-1187 (JS InnoPharm Ltd); HH-2710 (Shanghai Haihe Biopharma Co Ltd); JRP-890 (Prous Institute for Biomedical Research SA); JRF-108 (Chengdu Jinrui Foundation Biotechnology Co Ltd); BI ERKi (Boehringer Ingelheim); CC-90003 (BMS); ERAS-007 (Erasca); HMPL-295 (Hutchmed); IPN-ERK (Ipsen); KO-947 (Kura Oncology); LTT462 (Novartis); SCH772984 (Astex Pharmaceuticals); TK216 (Oncternal Therapeutics), and hydrates, solvates, and pharmaceutically acceptable salts thereof.
• the ERK 1/2 inhibitor is ASTX-029 (Astex Pharmaceuticals), HH-2710 (Shanghai Haihe Biopharma Co Ltd), LY-3214996 (Eli Lilly and Co), ulixertinib, ASN-007 (Asana BioSciences), ATG-017 (Antegene Corp), BPI-27336 (Betta Pharmaceuticals Co Ltd), JSL1187 (JS InnoPharm Ltd, Shanghai), MK-8353 (Merck), JRP- 890 (Prous Institute for Biomedical Research SA), JRF-108 (Chengdu Jinrui Foundation Biotechnology Co Ltd), or ravoxertinib, or a hydrate, solvate, or pharmaceutically acceptable salt thereof.
• the ERK1/2 inhibitor is administered at least once a week. In some embodiments, the ERK1/2 inhibitor is administered at least once daily. In some embodiments, the ERK1/2 inhibitor is administered once daily. In some embodiments, the ERK1/2 inhibitor is administered twice daily. In some embodiments, the ERK1/2 inhibitor is administered orally.
• the ERK1/2 inhibitor is dosed at about 0.1 mg to about 5000 mg, e.g., about 1 mg to about 3000 mg, about 1 mg to about 1000 mg, about 1 mg to about 500 mg, about 1 mg to about 100 mg, about 10 mg to about 2000 mg, e.g., about 100 mg to about 2000 mg, about 100 mg to about 1500 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 100 mg to about 200 mg, about 200 mg to about 2000 mg, about 200 mg to about 1500 mg, about 200 mg to about 1000 mg, about 200 mg to about 800 mg, about 200 mg to about 600 mg, about 200 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about 600 mg, about 600 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about
• the ERK1/2 inhibitor is dosed at about 1 mg per administration. In some embodiments, the ERK1/2 inhibitor is dosed at about 5 mg per administration. In some embodiments, the ERK1/2 inhibitor is dosed at about 10 mg per administration. In some embodiments, the ERK1/2 inhibitor is dosed at about 50 mg per administration. In some embodiments, the ERK1/2 inhibitor is dosed at about 100 mg per administration. In some embodiments, the ERK1/2 inhibitor is dosed at about 200 mg per administration. In some embodiments, the ERK1/2 inhibitor is dosed at about 300 mg per administration. In some embodiments, the ERK1/2 inhibitor is dosed at about 400 mg per administration. In some embodiments, the ERK1/2 inhibitor is dosed at about 500 mg per administration.
• the ERK1/2 inhibitor is dosed at about 600 mg per administration. In some embodiments, the ERK1/2 inhibitor is dosed at about 700 mg per administration. In some embodiments, the ERK1/2 inhibitor is dosed at about 800 mg per administration. In some embodiments, the ERK1/2 inhibitor is dosed at about 900 mg per administration. In some embodiments, the ERK1/2 inhibitor is dosed at about 1000 mg per administration.
• CDK4/6 inhibitors examples include, but are not limited to:
• Lerociclib having the following structure:
• SRX-3177 (SignalRx Pharmaceuticals Inc), having the following structure:
• RMC-4550 (Revolution Medicines Inc), having the following structure:
• GLR-2007 (Gan and Lee Pharmaceuticals), RP-CDK4/6 (Rhizen Pharmaceuticals); TQB 3303 (Chia Tai Tianqing Pharmaceutical); Trilaciclib (G1 Therapeutics); FCN-437c (Fochon Pharmaceutical Ltd); XZP-3287 (Sihuan Pharmaceutical Holdings Group Ltd); BEBT-209 (Guangzhou BeBetter Medicine Technology Co Ltd); BPI-16350 (Betta Pharmaceuticals Co Ltd); CS-3002 (CStone Pharmaceuticals Co Ltd); HS-10342 (Jiangsu Hansoh Pharmaceutical Group Co Ltd); TY-302 (Tetranov International Inc); Voruciclib; BPI-1178 (Beta Pharma Inc); NUV-422 (Nuvation Bio Inc); AU-294 (Aucentra Therapeutics Pty Ltd); ETH-155008 (Shengke Pharmaceuticals Ltd, Jiangsu); HEC-80797 (HEC Pharm Co Ltd); JS-104
• the CDK4/6 inhibitor is SHR-6390, FCN-437c, Lerociclib, Milciclib, PF-06873600, XZP-3287, BEBT-209, BPI-16350, CS-3002, HS-10342, ON- 123300, TY-302, Voruciclib, BPI-1178, NUV-422, AU-294, ETH-155008, HEC-80797, JS- 104, PF-07220060, RMC-4550, SRX-3177, VS-2370, Palbociclib, Ribociclib (e.g., ribociclib succinate), Letrozole + Ribociclib succinate, or Abemaciclib, or a solvate, a hydrate, or a pharmaceutically acceptable salt thereof.
• Ribociclib e.g., ribociclib succinate
• Letrozole + Ribociclib succinate or Abemaciclib, or a solvate, a hydrate, or a pharmaceutical
• the CDK4/6 inhibitor is ETH-155008, HEC-80797, JS-104, PF-07220060, RMC-4550, SRX-3177, VS-2370, Palbociclib, Ribociclib (e.g., ribociclib succinate ), Letrozole + Ribociclib succinate, or Abemaciclib, or a solvate, a hydrate, or a pharmaceutically acceptable salt thereof.
• the CDK4/6 inhibitor is administered at least once a week. In some embodiments, the CDK4/6 inhibitor is administered at least once daily. In some embodiments, the CDK4/6 inhibitor is administered once daily. In some embodiments, the CDK4/6 inhibitor is administered twice daily. In some embodiments, the CDK4/6 inhibitor is administered orally.
• the CDK4/6 inhibitor is dosed at about 0.1 mg to about 5000 mg, e.g., about 1 mg to about 3000 mg, about 1 mg to about 1000 mg, about 1 mg to about 500 mg, about 1 mg to about 100 mg, about 10 mg to about 2000 mg, e.g., about 100 mg to about 2000 mg, about 100 mg to about 1500 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 100 mg to about 200 mg, about 200 mg to about 2000 mg, about 200 mg to about 1500 mg, about 200 mg to about 1000 mg, about 200 mg to about 800 mg, about 200 mg to about 600 mg, about 200 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about 600 mg, about 600 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about
• the CDK4/6 inhibitor is dosed at about 1 mg per administration. In some embodiments, the CDK4/6 inhibitor is dosed at about 5 mg per administration. In some embodiments, the CDK4/6 inhibitor is dosed at about 10 mg per administration. In some embodiments, the CDK4/6 inhibitor is dosed at about 50 mg per administration. In some embodiments, the CDK4/6 inhibitor is dosed at about 100 mg per administration. In some embodiments, the CDK4/6 inhibitor is dosed at about 200 mg per administration. In some embodiments, the CDK4/6 inhibitor is dosed at about 300 mg per administration. In some embodiments, the CDK4/6 inhibitor is dosed at about 400 mg per administration. In some embodiments, the CDK4/6 inhibitor is dosed at about 500 mg per administration.
• the CDK4/6 inhibitor is dosed at about 600 mg per administration. In some embodiments, the CDK4/6 inhibitor is dosed at about 700 mg per administration. In some embodiments, the CDK4/6 inhibitor is dosed at about 800 mg per administration. In some embodiments, the CDK4/6 inhibitor is dosed at about 900 mg per administration. In some embodiments, the CDK4/6 inhibitor is dosed at about 1000 mg per administration.
• AKT inhibitors include, but are not limited to: capivasertib; ipatasertib; afuresertib hydrochloride; miransertib mesylate; trametinib dimethyl sulfoxide + uprosertib; uprosertib; borussertib; LY-2503029 (Eli Lilly and Co); COTI-2 (Cotinga Pharmaceuticals Inc); MK-2206 + selumetinib sulfate (Merck & Co Inc); PTX-200 (Prescient Therapeutics Ltd); ARQ-751 (vevorisertib, Merck & Co Inc); ALM-301 (Almac Discovery Ltd); DC-120 (Guangzhou Institute of Biomedicine and Health); FXY-1 (Krisani Bio Sciences Pvt Ltd); JRP-890 (Prous Institute for Biomedical Research SA); KS-99 (Pennsylvania State University); NISC-6 (Pennsyl
• ONC-201 (Ohara Pharmaceutical Co Ltd), having the following structure:
• TAS-117 (Taiho Pharmaceutical Co Ltd), having the following structure:
• AT-13148 (Astex Pharmaceuticals Inc), having the following structure:
• the AKT inhibitor is capivasertib, ipatasertib, LY-2503029, afuresertib hydrochloride, COTI-2, miransertib mesylate, MK-2206, MK-2206 + selumetinib sulfate, ONC-201, PTX-200, TAS-117, trametinib dimethyl sulfoxide + uprosertib, uprosertib, ARQ-751, AT-13148, M2698, ALM-301, BAY-1125976, borussertib, DC-120, FXY-1, JRP-890, KS-99, NISC-6, RX-0201, or RX-0301, or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof.
• the AKT inhibitor is administered at least once a week. In some embodiments, the AKT inhibitor is administered at least once daily. In some embodiments, the AKT inhibitor is administered once daily. In some embodiments, the AKT inhibitor is administered twice daily. In some embodiments, the AKT inhibitor is administered orally.
• the AKT inhibitor is dosed at about 0.1 mg to about 5000 mg, e.g., about 1 mg to about 3000 mg, about 1 mg to about 1000 mg, about 1 mg to about 500 mg, about 1 mg to about 100 mg, about 10 mg to about 2000 mg, e.g., about 100 mg to about 2000 mg, about 100 mg to about 1500 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 100 mg to about 200 mg, about 200 mg to about 2000 mg, about 200 mg to about 1500 mg, about 200 mg to about 1000 mg, about 200 mg to about 800 mg, about 200 mg to about 600 mg, about 200 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about 600 mg, about 600 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about 600 mg
• the AKT inhibitor is dosed at about 1 mg per administration. In some embodiments, the AKT inhibitor is dosed at about 5 mg per administration. In some embodiments, the AKT inhibitor is dosed at about 10 mg per administration. In some embodiments, the AKT inhibitor is dosed at about 50 mg per administration. In some embodiments, the AKT inhibitor is dosed at about 100 mg per administration. In some embodiments, the AKT inhibitor is dosed at about 200 mg per administration. In some embodiments, the AKT inhibitor is dosed at about 300 mg per administration. In some embodiments, the AKT inhibitor is dosed at about 400 mg per administration. In some embodiments, the AKT inhibitor is dosed at about 500 mg per administration. In some embodiments, the AKT inhibitor is dosed at about 600 mg per administration.
• the AKT inhibitor is dosed at about 700 mg per administration. In some embodiments, the AKT inhibitor is dosed at about 800 mg per administration. In some embodiments, the AKT inhibitor is dosed at about 900 mg per administration. In some embodiments, the AKT inhibitor is dosed at about 1000 mg per administration.
• mTOR inhibitors include, but are not limited to: everolimus; zortress; sirolimus; temsirolimus; sirolimus albumin-bound; dactolisib tosylate; onatasertib; DTRMWXHS-12 + everolimus + pomalidomide (Zhejiang DTRM Biopharma LLC); bimiralisib; monepantel; sapanisertib; paclitaxel + sirolimus + tanespimycin (Co-D Therapeutics Inc); sirolimus; vistusertib; detorsertib; omipalisib; purinostat mesylate; NSC- 765844 (National Cancer Institute US); OSU-53 (Ohio State University); OT-043 (Onco Therapies Inc); PQR-514 (PIQUR Therapeutics AG); QR-213 (Qrono Inc); SN-202 (Sichuan Sinovation Bio-technology Co Ltd); SPR
• RMC-5552 (Revolution Medicines Inc), having the following structure:
• CC-115 (Bristol-Myers Squibb Co), having the following structure: ME-344 (MEI Pharma Inc), having the following structure:
• FT-1518 (FTGBio LLC), having the following structure:
• the mTOR inhibitor is everolimus, zortress, sirolimus, temsirolimus, sirolimus albumin-bound, dactolisib tosylate, onatasertib, DTRMWXHS-12 + everolimus + pomalidomide, bimiralisib, CC-115, monepantel, sapanisertib, sirolimus, vistusertib, detorsertib, FP-208, HEC-68498, LXI-15029, ME-344, PTX-367, WXFL- 10030390, XP-105, paclitaxel + sirolimus + tanespimycin, AL-58805, AL-58922, AUM-302, CA-102, CA-103, CT-365, DFN-529, DHM-25, FT-1518, NSC-765844, omipalisib, OSU- 53, OT-043, PQR-514, pur
• the mTOR inhibitor is administered at least once a week. In some embodiments, the mTOR inhibitor is administered at least once daily. In some embodiments, the mTOR inhibitor is administered once daily. In some embodiments, the mTOR inhibitor is administered twice daily. In some embodiments, the mTOR inhibitor is administered orally.
• the mTOR inhibitor is dosed at about 0.1 mg to about 5000 mg, e.g., about 1 mg to about 3000 mg, about 1 mg to about 1000 mg, about 1 mg to about 500 mg, about 1 mg to about 100 mg, about 10 mg to about 2000 mg, e.g., about 100 mg to about 2000 mg, about 100 mg to about 1500 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 100 mg to about 200 mg, about 200 mg to about 2000 mg, about 200 mg to about 1500 mg, about 200 mg to about 1000 mg, about 200 mg to about 800 mg, about 200 mg to about 600 mg, about 200 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about 600 mg, about 600 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about 600
• the mTOR inhibitor is dosed at about 1 mg per administration. In some embodiments, the mTOR inhibitor is dosed at about 5 mg per administration. In some embodiments, the mTOR inhibitor is dosed at about 10 mg per administration. In some embodiments, the mTOR inhibitor is dosed at about 50 mg per administration. In some embodiments, the mTOR inhibitor is dosed at about 100 mg per administration. In some embodiments, the mTOR inhibitor is dosed at about 200 mg per administration. In some embodiments, the mTOR inhibitor is dosed at about 300 mg per administration. In some embodiments, the mTOR inhibitor is dosed at about 400 mg per administration. In some embodiments, the mTOR inhibitor is dosed at about 500 mg per administration.
• the mTOR inhibitor is dosed at about 600 mg per administration. In some embodiments, the mTOR inhibitor is dosed at about 700 mg per administration. In some embodiments, the mTOR inhibitor is dosed at about 800 mg per administration. In some embodiments, the mTOR inhibitor is dosed at about 900 mg per administration. In some embodiments, the mTOR inhibitor is dosed at about 1000 mg per administration. pan-HER inhibitors
• pan-HER inhibitors include, but are not limited to:
• BDTX 189 having the following structure: and hydrates, solvates, and pharmaceutically acceptable salts thereof.
• the pan-HER inhibitor is ZW49, PB 357, MP 0274, VRN 07, BDTX 189, sapitinib, zenocutuzumab, poziotinib, mobocertinib, valitinib, pyrotinib, lapatinib, afatinib, neratinib, or dacomitinib, or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof.
• the pan-HER inhibitor is afatinib, or a pharmaceutically acceptable salt thereof.
• the pan-HER inhibitor is administered at least once a week. In some embodiments, the pan-HER inhibitor is administered at least once daily. In some embodiments, the pan-HER inhibitor is administered once daily. In some embodiments, the pan-HER inhibitor is administered twice daily. In some embodiments, the pan-HER inhibitor is administered orally.
• the pan-HER inhibitor is dosed at about 0.1 mg to about 5000 mg, e.g., about 1 mg to about 3000 mg, about 1 mg to about 1000 mg, about 1 mg to about 500 mg, about 1 mg to about 100 mg, about 10 mg to about 2000 mg, e.g., about 100 mg to about 2000 mg, about 100 mg to about 1500 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 100 mg to about 200 mg, about 200 mg to about 2000 mg, about 200 mg to about 1500 mg, about 200 mg to about 1000 mg, about 200 mg to about 800 mg, about 200 mg to about 600 mg, about 200 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about 600 mg, about 600 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about 600
• the pan-HER inhibitor is dosed at about 1 mg per administration. In some embodiments, the pan-HER inhibitor is dosed at about 5 mg per administration. In some embodiments, the pan-HER inhibitor is dosed at about 10 mg per administration. In some embodiments, the pan-HER inhibitor is dosed at about 50 mg per administration. In some embodiments, the pan-HER inhibitor is dosed at about 100 mg per administration. In some embodiments, the pan-HER inhibitor is dosed at about 200 mg per administration. In some embodiments, the pan-HER inhibitor is dosed at about 300 mg per administration. In some embodiments, the pan-HER inhibitor is dosed at about 400 mg per administration. In some embodiments, the pan-HER inhibitor is dosed at about 500 mg per administration.
• the pan-HER inhibitor is dosed at about 600 mg per administration. In some embodiments, the pan-HER inhibitor is dosed at about 700 mg per administration. In some embodiments, the pan-HER inhibitor is dosed at about 800 mg per administration. In some embodiments, the pan-HER inhibitor is dosed at about 900 mg per administration. In some embodiments, the pan-HER inhibitor is dosed at about 1000 mg per administration.
• Exemplary EGFR inhibitors include, but are not limited to:
• ASK-120067 (Jiangsu Aosaikang Pharmaceutical Co Ltd), having the following structure:
• BI-4020 having the following structure:
• BPI-7711 (Beta Pharma Inc), having the following structure:
• NRC -2694 (Mateo Pharma Ltd), having the following structure:
• SKLB-1028 (CSPC Pharmaceutical Group Ltd), having the following structure:
• TAS-6417 (Cullinan Oncology LLC), having the following structure:
• BAY-2476568 (Bayer), having the following structure: doxorubicin + erlotinib, futuximab + modotuximab, abivertinib maleate, ABP-1119 (AB Pharma Ltd), ABP-1130 (AB Pharma Ltd), afatinib, afatinib dimaleate, AG-101 (Arrogene Inc), AL-6802 (Jiangsu Simcere Pharmaceutical Co Ltd), almonertinib mesylate, AM-105 (AbClon Inc), amelimumab, amivantamab, AMX-3009 (Arromax Pharmatech Co Ltd), APL- 1898 (Wigen Biomedicine Technology (Shanghai) Co Ltd), BBT-176 (Bridge Biotherapeutics Inc), BEBT-108 (Guangzhou BeBetter Medicine Technology Co Ltd), BEBT-109 (Guangzhou BeBeter Medicine Technology Co Ltd), BH-2922 (Beijing Hanmi Pharmaceutical Co Ltd), BLU-4810 (Blueprint Medicines
• the EGFR inhibitor is doxorubicin + erlotinib, futuximab + modotuximab, abivertinib maleate, ABP-1119, ABP-1130, afatinib dimaleate, AG-101, AL- 6802, almonertinib mesylate, AM-105, amelimumab, amivantamab, AMX-3009, APL-1898, ASK-120067, AST-2818, BBT-176, BDTX-189, BEBT-108, BEBT-109, BH-2922, BLU- 4810, BMX-002, BO-1978, BPI-15086, BPI-7711, brigatinib, C-005, cetuximab, CK-101, CLM-29, CLM-3, CMAB-017, CR-13626, CSHEGF-29, D-0316, D2C7-IT + PVSRIPO, dabrafeni
• the EGFR inhibitor is afatinib, or a pharmaceutically acceptable salt thereof. In some embodiments, the EGFR inhibitor is osimertinib, or a pharmaceutically acceptable salt thereof. In some embodiments, the EGFR inhibitor is administered at least once a week. In some embodiments, the EGFR inhibitor is administered at least once daily. In some embodiments, the EGFR inhibitor is administered once daily. In some embodiments, the EGFR inhibitor is administered twice daily. In some embodiments, the EGFR inhibitor is administered orally.
• the EGFR inhibitor is dosed at about 0.1 mg to about 5000 mg, e.g., about 1 mg to about 3000 mg, about 1 mg to about 1000 mg, about 1 mg to about 500 mg, about 1 mg to about 100 mg, about 10 mg to about 2000 mg, e.g., about 100 mg to about 2000 mg, about 100 mg to about 1500 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 100 mg to about 200 mg, about 200 mg to about 2000 mg, about 200 mg to about 1500 mg, about 200 mg to about 1000 mg, about 200 mg to about 800 mg, about 200 mg to about 600 mg, about 200 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about 600 mg, about 600 mg to about 2000 mg, about 400 mg to about 1500 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg to about 600
• the EGFR inhibitor is dosed at about 1 mg per administration. In some embodiments, the EGFR inhibitor is dosed at about 5 mg per administration. In some embodiments, the EGFR inhibitor is dosed at about 10 mg per administration. In some embodiments, the EGFR inhibitor is dosed at about 50 mg per administration. In some embodiments, the EGFR inhibitor is dosed at about 100 mg per administration. In some embodiments, the EGFR inhibitor is dosed at about 200 mg per administration. In some embodiments, the EGFR inhibitor is dosed at about 300 mg per administration. In some embodiments, the EGFR inhibitor is dosed at about 400 mg per administration. In some embodiments, the EGFR inhibitor is dosed at about 500 mg per administration.
• the EGFR inhibitor is dosed at about 600 mg per administration. In some embodiments, the EGFR inhibitor is dosed at about 700 mg per administration. In some embodiments, the EGFR inhibitor is dosed at about 800 mg per administration. In some embodiments, the EGFR inhibitor is dosed at about 900 mg per administration. In some embodiments, the EGFR inhibitor is dosed at about 1000 mg per administration.
• a MEK inhibitor can be a small molecule or biologic inhibitor of the mitogen- activated protein kinase (MAPK) enzymes MEK1 and/or MEK2 (e.g., MAPKZERK pathway).
• MEK inhibitors include, but are not limited to:
• Trametinib also known as Mekinst, GSK1120212 having the following structure:
• WX-554 (Wilex); and HL-085 (Shanghai Kechow Pharma), and pharmaceutically acceptable salts thereof.
• the MEK inhibitor is selected from the group consisting of trametinib, cobimetinib, binimetinib, selumetinib, PD-325901, CI-1040, MEK162, AZD8330, GDC-0623, refametinib, pimasertib, WX-554, HL-085, CH4987655, TAK-733, CInQ-03, G-573, PD184161, PD318088, PD98059, R05068760, U0126, and SL327, or a pharmaceutically acceptable salt thereof.
• the MEK inhibitor is dosed at least once a week (e.g., once a week, twice a week, three times a week, four times a week, five times a week, or six times a week). In some embodiments, the MEK inhibitor is dosed once a week. In some embodiments, the MEK inhibitor is dosed twice a week. In some embodiments, the MEK inhibitor is dosed once daily. In some embodiments, the MEK inhibitor is dosed twice daily. In some embodiments, the MEK inhibitor is dosed for at least three weeks.
• the MEK inhibitor is dosed cyclically (as a cycle) for three weeks on and then one week off (administering the MEK inhibitor for three weeks and then not administering the MEK inhibitor for one week). In some embodiments, the cycle is repeated at least once. In other embodiments, the MEK inhibitor is dosed continuously (e.g., without the one week off).
• the MEK inhibitor is dosed at about 0.1 mg to about 100 mg, e.g., about 0.1 mg to about 50 mg, about 0.1 mg to about 10 mg, about 0.1 mg to about 5 mg, about 0.1 mg to about 4 mg, about 0.1 mg to about 3 mg, about 0.1 mg to about 2 mg, about 0.1 mg to about 1 mg, about 1 mg to about 10 mg, about 1 mg to about 20 mg, about 1 mg to about 40 mg, about 1 mg to about 60 mg, about 1 mg to about 80 mg, about 1 mg to about 100 mg, about 10 mg to about 100 mg, about 20 mg to about 100 mg, about 40 mg to about 100 mg, about 60 mg to about 100 mg, or about 80 mg to about 100 mg per administration.
• the MEK inhibitor is dosed at about 0.5 mg to about 10 mg per administration. In some embodiments, the MEK inhibitor is dosed at about 0.1 mg, 0.2 mg, 0.5 mg, 1 mg, 1.5 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 100 mg per administration. In some embodiments, the MEK inhibitor is dosed at about 4 mg per administration. In some embodiments, the MEK inhibitor is dosed at about 3.2 mg per administration.
• the MEK inhibitor is administered orally.
• the MEK inhibitor is administered before the SHP2 inhibitor, the S0S1 inhibitor, the ERK1/2 inhibitor, the CDK4/6 inhibitor, the AKT inhibitor, the mTOR inhibitor, the pan-HER inhibitor, or the EGFR inhibitor is administered. In some embodiments, the MEK inhibitor is administered after the SHP2 inhibitor, the S0S1 inhibitor, the ERK1/2 inhibitor, the CDK4/6 inhibitor, the AKT inhibitor, the mTOR inhibitor, the pan-HER inhibitor, or the EGFR inhibitor is administered.
• the MEK inhibitor is administered concurrently with the SHP2 inhibitor, the S0S1 inhibitor, the ERK1/2 inhibitor, the CDK4/6 inhibitor, the AKT inhibitor, the mTOR inhibitor, the pan-HER inhibitor, or the EGFR inhibitor.
• the dual RAF/MEK inhibitor is a compound of formula (I):
• the compound of formula (I) is: which is also referred to herein as Compound 1 or VS-6766 free form.
• the dual RAF/MEK inhibitor is a pharmaceutically acceptable salt of the compound of formula (I).
• the dual RAF/MEK inhibitor is a potassium salt of the compound of formula (I), which is also referred to as VS-6766.
• Other pharmaceutically acceptable salts of the compound of formula (I) are contemplated herein.
• the compound of formula (I), and pharmaceutically acceptable salts thereof are dual RAF/MEK inhibitors that confer vertical inhibition of the MAPK pathway.
• the compound of formula (I), and pharmaceutically acceptable salts thereof are potent allosteric inhibitors of MEK kinase activity which promotes a dominant negative RAF/MEK complex preventing phosphorylation of MEK by wild-type RAF, V600E BRAF and CRAF. This mechanism allows the compound of formula (I), and pharmaceutically acceptable salts thereof, to block MEK signaling without the compensatory activation of MEK that appears to limit the efficacy of other inhibitors.
• the dual RAF/MEK inhibitor is a compound having the structure of Formula (II): including pharmaceutically acceptable salts thereof, wherein:
• R 1 , R 2 , R 3 , and R 4 are each independently selected from the group consisting of H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N- thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted Cl to C6 alkoxy, optionally substituted Cl to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalky
• L is -Z1-Z2 or -Z1-Z2-Z3;
• Y is CH 2 , NH, or O, with the proviso that R 1 is not -O-pyrimidyl.
• the dual RAF/MEK inhibitor is a compound selected from a compound in Table I:
• the dual RAF/MEK inhibitor is IMM-1-104 (Immuneering) or a pharmaceutically acceptable salt thereof.
• the dual RAF/MEK inhibitor is dosed at least once a week (e.g., once a week, twice a week, three times a week, four times a week, five times a week, or six times a week). In some embodiments, the dual RAF/MEK inhibitor is dosed once a week. In some embodiments, the dual RAF/MEK inhibitor is dosed twice a week. In some embodiments, the dual RAF/MEK inhibitor is dosed once daily. In some embodiments, the dual RAF/MEK inhibitor is dosed twice daily. In some embodiments, the dual RAF/MEK inhibitor is dosed for at least three weeks.
• the dual RAF/MEK inhibitor is dosed cyclically (as a cycle) for three weeks on and then one week off (administering the dual RAF/MEK inhibitor for three weeks and then not administering the dual RAF/MEK inhibitor for one week).
• the cycle is repeated at least once.
• the dual RAF/MEK inhibitor is dosed continuously (e.g., without the one week off).
• the dual RAF/MEK inhibitor is dosed at about 0.1 mg to about 100 mg, e.g., about 0.1 mg to about 50 mg, about 0.1 mg to about 10 mg, about 0.1 mg to about 5 mg, about 0.1 mg to about 4 mg, about 0.1 mg to about 3 mg, about 0.1 mg to about 2 mg, about 0.1 mg to about 1 mg, about 1 mg to about 10 mg, about 1 mg to about 20 mg, about 1 mg to about 40 mg, about 1 mg to about 60 mg, about 1 mg to about 80 mg, about 1 mg to about 100 mg, about 10 mg to about 100 mg, about 20 mg to about 100 mg, about 40 mg to about 100 mg, about 60 mg to about 100 mg, or about 80 mg to about 100 mg per administration.
• the dual RAF/MEK inhibitor is dosed at about 0.5 mg to about 10 mg per administration. In some embodiments, the dual RAF/MEK inhibitor is dosed at about 0.1 mg, 0.2 mg, 0.5 mg, 1 mg, 1.5 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 100 mg per administration. In some embodiments, dual RAF/MEK inhibitor is dosed at about 4 mg per administration. In some embodiments, the dual RAF/MEK inhibitor is dosed at about 3.2 mg per administration.
• the dual RAF/MEK inhibitor (e.g., VS-6766) is dosed at about 4 mg twice a week. In some embodiments, the dual RAF/MEK inhibitor (e.g., VS-6766) is dosed at about 3.2 mg twice a week.
• the dual RAF/MEK inhibitor is administered orally.
• the dual RAF/MEK inhibitor is dosed cyclically for three weeks on and then one week off (administering the dual RAF/MEK inhibitor for three weeks and then not administering the dual RAF/MEK inhibitor for one week).
• the cycle is repeated at least once.
• the cycle is repeated at least twice.
• the cycle is repeated at least thrice.
• the dual RAF/MEK inhibitor is dosed twice a week.
• the dual RAF/MEK inhibitor is dosed at about 0.5 mg to about 10 mg (e.g., about 4 mg or about 3.2 mg) per administration.
• the dual RAF/MEK inhibitor is dosed at about 0.1 mg to about 5 mg per administration. In some embodiments, the dual RAF/MEK inhibitor is dosed at about 1 mg to about 5 mg per administration. In some embodiments, the dual RAF/MEK inhibitor is dosed at about 2 mg to about 4 mg per administration.
• the dual RAF/MEK inhibitor is dosed twice a week as a cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor for three weeks at a dose of about 0.5 mg to about 10 mg per administration and then not administering the dual RAF/MEK inhibitor for one week.
• the dual RAF/MEK inhibitor is dosed twice a week as a cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor for three weeks at a dose of about 1 mg to about 5 mg per administration and then not administering the dual RAF/MEK inhibitor for one week.
• the dual RAF/MEK inhibitor is dosed twice a week as a cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor for three weeks at a dose of about 2 mg to about 4 mg per administration and then not administering the dual RAF/MEK inhibitor for one week.
• the dual RAF/MEK inhibitor is dosed twice a week as a cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor for three weeks at a dose of 3.2 mg per administration and then not administering the dual RAF/MEK inhibitor for one week.
• the dual RAF/MEK inhibitor is dosed twice a week as a cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor for three weeks at a dose of 4 mg per administration and then not administering the dual RAF/MEK inhibitor for one week. In some embodiments, the cycle is repeated at least once.
• the dual RAF/MEK inhibitor is dosed thrice a week as a cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor for three weeks at a dose of about 0.8 mg to about 10 mg per administration and then not administering the dual RAF/MEK inhibitor for one week.
• the dual RAF/MEK inhibitor is dosed thrice a week as a cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor for three weeks at a dose of about 1 mg to about 5 mg per administration and then not administering the dual RAF/MEK inhibitor for one week.
• the dual RAF/MEK inhibitor is dosed thrice a week as a cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor for three weeks at a dose of about 2 mg to about 4 mg per administration and then not administering the dual RAF/MEK inhibitor for one week.
• the dual RAF/MEK inhibitor is dosed thrice a week as a cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor for three weeks at a dose of 3.2 mg per administration and then not administering the dual RAF/MEK inhibitor for one week.
• the dual RAF/MEK inhibitor is dosed thrice a week as a cycle, wherein the cycle comprises administering the dual RAF/MEK inhibitor for three weeks at a dose of 4 mg per administration and then not administering the dual RAF/MEK inhibitor for one week. In some embodiments, the cycle is repeated at least once.
• the dual RAF/MEK inhibitor is dosed continuously (i.e., without a period of time, e.g., one week, wherein the dual RAF/MEK inhibitor is not administered). In some embodiments, the dual RAF/MEK inhibitor is dosed once a week. In some embodiments, the dual RAF/MEK inhibitor is dosed twice a week. In some embodiments, the dual RAF/MEK inhibitor is dosed three times a week.
• the dual RAF/MEK inhibitor is administered before the SHP2 inhibitor, the S0S1 inhibitor, the ERK1/2 inhibitor, the CDK4/6 inhibitor, the AKT inhibitor, the mTOR inhibitor, the pan-HER inhibitor, or the EGFR inhibitor is administered. In some embodiments, the dual RAF/MEK inhibitor is administered after the SHP2 inhibitor, the S0S1 inhibitor, the ERK1/2 inhibitor, the CDK4/6 inhibitor, the AKT inhibitor, the mTOR inhibitor, the pan-HER inhibitor, or the EGFR inhibitor is administered.
• the dual RAF/MEK inhibitor is administered concurrently with the SHP2 inhibitor, the S0S1 inhibitor, the ERK1/2 inhibitor, the CDK4/6 inhibitor, the AKT inhibitor, the mTOR inhibitor, the pan-HER inhibitor, or the EGFR inhibitor.
• the cancer may include, but is not limited to, ovarian cancer, non-small cell lung cancer (e.g., NSCLC adenocarcinoma)), uterine endometrioid carcinoma, pancreatic adenocarcinoma, colorectal adenocarcinoma, or lung adenocarcinoma.
• NSCLC adenocarcinoma non-small cell lung cancer
• uterine endometrioid carcinoma uterine endometrioid carcinoma
• pancreatic adenocarcinoma pancreatic adenocarcinoma
• colorectal adenocarcinoma or lung adenocarcinoma.
• Methods provided herein are also contemplated as being useful for the treatment of a cancer identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)).
• the cancer is characterized as having a KRAS mutation (e.g., KRAS G12X mutation (e g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)).
• the cancer is identified as having one or more KRAS mutation.
• the KRAS mutation is a KRAS G12X mutation.
• the KRAS mutation is KRAS G12V mutation.
• the KRAS mutation is KRAS G12D mutation.
• the KRAS mutation is KRAS G12A mutation.
• the KRAS mutation is KRAS G12R mutation.
• the KRAS mutation is KRAS G12S mutation.
• the KRAS mutation is KRAS G12C mutation.
• the KRAS mutation is a KRAS G13X mutation.
• the KRAS mutation is KRAS G13V mutation. In some embodiments, the KRAS mutation is KRAS G13D mutation. In some embodiments, the KRAS mutation is KRAS G13A mutation. In some embodiments, the KRAS mutation is KRAS G13R mutation. In some embodiments, the KRAS mutation is KRAS G13S mutation. In some embodiments, the KRAS mutation is KRAS G13E mutation. In some embodiments, the KRAS mutation is KRAS G12 dup mutation. In some embodiments, the KRAS mutation is KRAS G13C mutation. In some embodiments, the KRAS mutation is a KRAS Q61X mutation.
• the KRAS mutation is KRAS Q61H mutation. In some embodiments, the KRAS mutation is KRAS Q61K mutation. In some embodiments, the KRAS mutation is KRAS Q61L mutation. In some embodiments, the KRAS mutation is KRAS Q61R mutation. In some embodiments, the KRAS mutation is KRAS Q61P mutation. In some embodiments, the KRAS mutation is KRAS Q61E mutation.
• Methods provided herein are also contemplated as being useful for the treatment of a cancer identified as having a RAS pathway mutation such as KRAS, NRAS, or HRAS.
• the cancer is identified as having a HRAS mutation. In some embodiments, the cancer is identified as having a NRAS mutation. In some embodiments, the cancer is identified as having a RAF mutation.
• the cancer is identified as having a BRAF mutation.
• the BRAF mutation is BRAF V600 mutation.
• the BRAF V600 mutation is one or more BRAF V600E, BRAF V600K, BRAF V600D, BRAF V600R, or BRAF V600M mutation.
• the BRAF V600 mutation is BRAF V600E mutation.
• the BRAF V600 mutation is BRAF V600K mutation.
• the BRAF V600 mutation is BRAF V600D mutation.
• the BRAF V600 mutation is BRAF V600R mutation.
• the BRAF V600 mutation is BRAF V600M mutation.
• the cancer is identified as having a ARAF mutation. In some embodiments, the cancer is identified as having a CRAF mutation. In some embodiments, the cancer is identified as having MEK1 and/or MEK2 mutation.
• the cancer is identified as having NF1 alterations, KRAS amplification, and/or NRAS amplification.
• the cancer is identified as having positive phospho-ERK protein expression (e.g., > 10%, > 20% or > 30% of cells) detected by immunohi stochemi stry .
• the cancer is identified as having EGFR alterations.
• Abnormal cell growth refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) that proliferate, for example, by expressing a mutated tyrosine kinase or overexpression of a receptor tyrosine kinase; (2) benign and malignant cells of other proliferative diseases, for example, in which aberrant tyrosine kinase activation occurs; (3) any tumors that proliferate, for example, by receptor tyrosine kinases; (4) any tumors mat proliferate, for example, by aberrant serine/threonine kinase activation; and (5) benign and malignant cells of other proliferative diseases, for example, in which aberrant serine/threonine kinase activation occurs.
• tumor cells tumor cells that proliferate, for example, by expressing a mutated tyrosine kinase or overexpression of a
• Abnormal cell growth can refer to cell growth in epithelial (e.g., carcinomas, adenocarcinomas): mesenchymal (e.g., sarcomas (e.g. leiomyosarcoma. Ewing's sarcoma)); hematopoetic (e.g., lymphomas, leukemias, myelodysplasias (e.g., pre-malignant)); or other (e.g., melanoma, mesothelioma, and other tumors of unknown origin) cell.
• epithelial e.g., carcinomas, adenocarcinomas
• mesenchymal e.g., sarcomas (e.g. leiomyosarcoma. Ewing's sarcoma)
• hematopoetic e.g., lymphomas, leukemias, myelodysplasias (e.g., pre-
• Abnormal cell growth can refer to a neoplastic disorder.
• a "neoplastic disorder” is a disease or disorder characterized by cells that have the capacity for autonomous growth or replication, e.g., an abnormal state or condition characterized by proliferative cell growth.
• An abnormal mass of tissue as a result of abnormal cell growth or division, or a "neoplasm,” can be benign, pre-malignant (carcinoma in situ) or malignant (cancer).
• neoplastic disorders include: carcinoma, sarcoma, metastatic disorders (e.g., tumors arising from prostate, colon, lung, breast and liver origin), hematopoietic neoplastic disorders, e.g., leukemias, metastatic tumors. Treatment with the compound maybe in an amount effective to ameliorate at least one symptom of the neoplastic disorder, e.g., reduced cell proliferation, reduced tumor mass, etc.
• metastatic disorders e.g., tumors arising from prostate, colon, lung, breast and liver origin
• hematopoietic neoplastic disorders e.g., leukemias, metastatic tumors.
• Treatment with the compound maybe in an amount effective to ameliorate at least one symptom of the neoplastic disorder, e.g., reduced cell proliferation, reduced tumor mass, etc.
• inventive methods of the present invention may be useful in the prevention and treatment of cancer, including for example, solid tumors, soft tissue tumors, and metastases thereof.
• the disclosed methods are also useful in treating non-solid cancers.
• Exemplary- solid tumors include malignancies (e.g., sarcomas, adenocarcinomas, and carcinomas) of the various organ systems, such as those of lung, breast, lymphoid, gastrointestinal (e.g., colon), and genitourinary (e.g., renal, urothelial, or testicular tumors) tracts, pharynx, prostate, and ovary.
• Exemplary- adenocarcinomas include colorectal cancers, renal-cell carcinoma, liver cancer (e.g.. Hepatocellular carcinoma), non-small cell carcinoma of the lung, pancreatic (e.g., metastatic pancreatic adenocarcinoma) and cancer of the small intestine.
• the cancer can include esophageal squamous cell carcinoma (ESCC); gastrointestinal stromal tumor (GIST); head and neck cancer squamous cell carcinoma, bladder cancer; colorectal cancer, pancreatic ductal carcinoma; triple-negative breast cancer (TNBC), mesothelioma; neurofibromatosis; e.g., neurofibromatosis type 2, neurofibromatosis type 1; renal cancer; lung cancer, non small cell lung cancer; liver cancer; thyroid cancer, ovarian, breast cancer; a nervous system tumor; schwannoma; meningioma; schwannomatosis; neuroma acoustic; adenoid cystic carcinoma; ependymoma; ependymal tumors, or any other tumor which exhibits decreased merlin expression and/or mutation, and/or deletion and/or promotor hypermethylation of the NF-2 gene.
• the cancer is renal cancer.
• the cancer can include cancers characterized as comprising cancer stem cells, cancer associated mesenchymal cells, or tumor initiating cancer cells.
• the cancer can include cancers that have been characterized as being enriched with cancer stem cells, cancer associated mesenchymal cells, or tumor initialing cancer cells (e.g., a tumor enriched with cells that have undergone an epithelial-to-mesenchymal transition or a metastatic tumor).
• the cancer can be a primary tumor, i.e., located at the anatomical site of tumor growth initiation.
• the cancer can also be metastatic, i.e., appearing at least a second anatomical site other than the anatomical site of tumor growth initiation.
• the cancer can be a recurrent cancer, i.e., cancer that returns following treatment, and after a period of time in which the cancer was undetectable.
• the recurrent cancer can be anatomically located locally to the original tumor, e.g., anatomically near the original tumor; regionally to the original tumor, e.g., in a lymph node located near the original tumor; or distantly to the original tumor, e.g., anatomically in a region remote from the original tumor.
• the cancer can also include for example, but is not limited to, epithelial cancers, breast, lung, pancreatic, colorectal (e.g., metastatic colorectal, e.g., metastatic KRAS mutated), prostate, head and neck, melanoma (e.g., NRAS mutated locally advanced or metastatic malignant cutaneous melanoma), acute myelogenous leukemia, and glioblastoma.
• Exemplary' breast cancers include triple negative breast cancer, basal -like breast cancer, claudin-low breast cancer, invasive, inflammatory’, metaplastic, and advanced HER-2 positive or ER-positive cancers resistant to therapy.
• the cancer can also include a cancer with a SHP2 mutation, S0S1 mutation, ERK1/2 mutation CDK 4/6 mutation, AKT mutation, mTOR mutation, pan-HER mutation, or EGFR alteration.
• the cancer can also include lung adenocarcinoma, colorectal cancer, uterine endometrioid carcinoma, bladder urothelial carcinoma, breast invasive lobular carcinoma, cervical squamous cell carcinoma, cutaneous melanoma, endocervical adenocarcinoma, hepatocellular carcinoma, pancreatic adenocarcinoma, biphasic type pleural mesothelioma, renal clear cell carcinoma, renal clear cell carcinoma, stomach adenocarcinoma, tubular stomach adenocarcinoma, uterine carcinosarcoma, or uterine malignant mixed Mullerian tumor.
• cancers include but are not limited to, uveal melanoma, brain, abdominal, esophagus, gastrointestinal, glioma, liver, tongue, neuroblastoma, osteosarcoma, ovarian, retinoblastoma, Wilm's tumor, multiple myeloma, skin, lymphoma, blood and bone marrow cancers (e.g., advanced hematological malignancies, leukemia, e.g., acute myeloid leukemia (e.g., primary or secondary’), acute lymphoblastic leukemia, acute lymphocytic leukemia, T cell leukemia, hematological malignancies, advanced myeloproliferative disorders, myelodysplastic syndrome, relapsed or refractory' multiple myeloma, advanced myeloproliferative disorders), retinal, bladder, cervical, kidney, endometrial, meningioma, lymphoma, skin, uterine, lung, non
• the tumor is a solid tumor.
• the solid tumor is locally advanced or metastatic, hi some embodiments, the solid tumor is refractory' (e.g., resistant) after standard therapy.
• the cancer is lung cancer (e.g., non-small cell lung cancer NSCLC), e.g., KRAS mutant NSCLC; metastatic cancer), bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer (e.g., unresectable low-grade ovarian, advanced or metastatic ovarian cancer), rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer (e.g., triple-negative breast cancer (e.g., breast cancer which does not express the genes for the estrogen receptor, progesterone receiptor, and Her2/neu)), uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus (esophageal cancer), cancer of the small intestine, cancer of the endocrine system,
• Methods described herein can reduce, ameliorate or altogether eliminate the disorder, and/or its associated symptoms, to keep it from becoming worse, to slow the rate of progression, or to minimize the rate of recurrence of the disorder once it has been initially eliminated (i.e., to avoid a relapse).
• a suitable dose and therapeutic regimen may vary depending upon the specific compounds, combinations, and/or pharmaceutical compositions used and the mode of delivery of the compounds, combinations, and/or pharmaceutical compositions.
• the method increases the average length of survival, increases the average length of progression-free survival, and/or reduces the rate of recurrence, of subjects treated with the combinations described herein in a statistically significant manner.
• the methods and compositions described herein is administered together with an additional therapy (e.g., cancer treatment).
• an additional therapy e.g., cancer treatment
• a mixture of one or more compounds or pharmaceutical compositions may be administered with the combination described herein to a subject in need thereof.
• one or more compounds or compositions e.g., pharmaceutical compositions
• combination therapies comprising a compound or pharmaceutical composition described herein may refer to (1) pharmaceutical compositions that comprise one or more compounds in combination with the combination described herein; and (2) coadministration of one or more compounds or pharmaceutical compositions described herein with the combination described herein, wherein the compound or pharmaceutical composition described herein have not been formulated in the same compositions.
• the combinations described herein is administered with an additional treatment (e.g., an additional cancer treatment).
• the additional treatment e.g., an additional cancer treatment
• the additional treatment can be administered simultaneously (e.g., at the same time), in the same or in separate compositions, or sequentially.
• Sequential administration refers to administration of one treatment before (e.g., immediately before, less than 5, 10, 15, 30, 45, 60 minutes, 1 , 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 48, 72, 96 or more hours; 4, 5, 6, 7, 8, 9 or more days; 1 , 2, 3, 4, 5, 6, 7, 8 or more weeks before) administration of an additional, e.g., secondary, treatment (e.g., a compound or therapy).
• additional, e.g., secondary, treatment e.g., a compound or therapy.
• the order of administration of the first and secondary compound or therapy can also be reversed.
• Exemplary cancer treatments include, for example: chemotherapy, targeted therapies such as antibody therapies, immunotherapy, and hormonal therapy. Examples of each of these treatments are provided below.
• a combination described herein is administered with a chemotherapy.
• Chemotherapy is the treatment of cancer with drugs that can destroy cancer cells. "Chemotherapy " usually refers to cytotoxic drugs which affect rapidly dividing cells in general, in contrast with targeted therapy. Chemotherapy drugs interfere with cell division in various possible ways, e.g., with the duplication of DNA or the separation of newly formed chromosomes. Most forms of chemotherapy target all rapidly dividing cells and are not specific for cancer cells, although some degree of specificity may come from the inability of many cancer cells to repair DNA damage, while normal cells generally can.
• Exampl es of chemotherapeutic agents used in cancer therapy include, for example, antimetabolites (e.g., folic acid, purine, and pyrimidine derivatives) and alkylating agents (e.g., nitrogen mustards, nitrosoureas, platinum, alkyl sulfonates, hydrazines, triazenes, aziridines, spindle poison, cytotoxic agents, toposimerase inhibitors and others).
• alkylating agents e.g., nitrogen mustards, nitrosoureas, platinum, alkyl sulfonates, hydrazines, triazenes, aziridines, spindle poison, cytotoxic agents, toposimerase inhibitors and others.
• Exemplary agents include Aclarubicin, Actinomycin, Alitretinon, Altretaniine, Aminopterin, Aminolevulinic acid, Amrubicin, Amsacrine, Anagrelide, Arsenic tri
• Pirarubicin Pixanlrone. Plicamvcin, Porfimer sodium, Prednimu stine. Procarbazine, Raltitrexed, Ranimustine, Rubitecan, Sapacitabine, Semustine, Sitimagene ceradenovec, Strataplatin, Streptozocin, Talaporfm, Tegafur-uracil, Temoporfm, Temozolomide, Teniposide, Tesetaxel, Testolactone, Tetranitrate, Thiotepa, Tiazofurine, Tioguanine, Tipifamib, Topotecan, Trabectedin, Triaziquone, Triethylenemelamine, Triplatin, Tretinoin, Treosulfan, Trofosfamide, Uramustine, Valrubicin, Verteporfm, Vinblastine, Vincristine, Vindesine, Vinflunine, Vinorelbine, Vorinostat, Zorubicin,
• the chemotherapy agents can be used in combination with a combination described herein.
• a combination described herein is administered with a targeted therapy.
• Targeted therapy constitutes the use of agents specific for the deregulated proteins of cancer cells.
• Small molecule targeted therapy drugs are generally inhibitors of enzymatic domains on mutated, overexpressed, or otherwise critical proteins within the cancer cell.
• Prominent examples are the tyrosine kinase inhibitors such as Axitinib, Bosutinib, Cediranib, desatinib, erolotinib, imatinib, gefitinib, lapatinib, Lestaurtinib, Nilotinib, Semaxanib, Sorafenib, Sunitinib, and Vandetanib, and also cyclin-depdendent kinase inhibitors such as Alvocidib and Seliciclib.
• Monoclonal antibody therapy is another strategy in which the therapeutic agent is an antibody which specifically binds to a protein on the surface of the cancer cells.
• Examples include the anti-HER2/neu antibody trastuzumab (HERCEPTIN®) typically used in breast cancer, and the anti-CD20 antibody rituximab and Tositumomab typically used in a variety of B-cell malignancies.
• Other exemplary anbitodies include Ctuximab, Panitumumab, Trastuzumab, Alemtuzumab, Bevacizumab, Edrecolomab, and Gemtuzumab.
• Exemplary fusion proteins include Aflibercept and Denileukin diftitox.
• the targeted therapy can be used in combination with a combination described herein.
• Targeted therapy can also involve small peptides as "homing devices” which can bind to cell surface receptors or affected extracellular matrix surrounding the tumor. Radionuclides which are attached to these peptides (e.g., RGDs) eventually kill the cancer cell if the nuclide decay s in the vicinity of the cell.
• RGDs Radionuclides which are attached to these peptides
• An example of such therapy includes BEXXAR®.
• a combination described herein is administered with an immunotherapy.
• Cancer immunotherapy refers to a diverse set of therapeutic strategies designed to induce the patient's own immune system to fight the tumor.
• Contemporary methods for generating an immune response against tumors include intravesicular BCG immunotherapy for superficial bladder cancer, and use of interferons and other cytokines to induce an immune response in subjects with renal cell carcinoma and melanoma.
• Allogeneic hematopoietic stem cell transplantation can be considered a form of immunotherapy, since the donor's immune cells will often attack the tumor in a graft- versus- tumor effect.
• the immunotherapy agents can be used in combination with a combination as described herein.
• a combination described is administered with a hormonal therapy.
• the growth of some cancers can be inhibited by providing or blocking certain hormones.
• hormone-sensitive tumors include certain types of breast and prostate cancers. Removing or blocking estrogen or testosterone is often an important additional treatment.
• administration of hormone agonists, such as progestagens may be therapeutically beneficial.
• the hormonal therapy agents can be used in combination with a combination described herein.
• the combinations described herein can be used in combination with directed energy or particle, or radioisotope treatments, e.g., radiation therapies, e.g., radiation oncology, for the treatment of proliferative disease, e.g., cancer, e.g., cancer associated with cancer stem cells.
• the combinations described herein may be administered to a subject simultaneously or sequentially along with the directed energy or particle, or radioisotope treatments.
• the combinations described herein may be administered before, during, or after the directed energy or particle, or radioisotope treatment, or a combination thereof.
• the directed energy or particle therapy may comprise total body irradiation, local body irradiation, or point irradiation.
• the directed energy or particle may originate from an accelerator, synchrotron, nuclear reaction, vacuum tube, laser, or from a radioisotope.
• the therapy may comprise external beam radiation therapy, teletherapy, brachy therapy, sealed source radiation therapy, systemic radioisotope therapy , or unsealed source radiotherapy.
• the therapy may comprise ingestion of, or placement in proximity to, a radioisotope, e.g., radioactive iodine, cobalt, cesium, potassium, bromine, fluorine, carbon.
• External beam radiation may comprise exposure to directed alpha particles, electrons (e.g., beta particles), protons, neutrons, positrons, or photons (e.g., radiowave, millimeter wave, microwave, infrared, visible, ultraviolet, X-ray, or gamma-ray photons).
• the radiation may be directed at any portion of the subject in need of treatment.
• the combinations described herein can be used in combination with surgery, e.g., surgical exploration, intervention, biopsy, for the treatment of proliferative disease, e.g., cancer, e.g., cancer associated with cancer stem cells.
• the combinations described herein may be administered to a subject simultaneously or sequentially along with the surgery.
• the combinations described herein may be administered before (preoperative), during, or after (post-operative) the surgery, or a combination thereof.
• the surgery may be a biopsy during which one or more cells are collected for further analysis.
• the biopsy may be accomplished, for example, with a scalpel, a needle, a catheter, an endoscope, a spatula, or scissors.
• the biopsy may be an excisional biopsy, an incisional biopsy, a core biopsy, or a needle biopsy, e.g., a needle aspiration biopsy.
• the surgery may involve the removal of localized tissues suspected to be or identified as being cancerous.
• the procedure may involve the removal of a cancerous lesion, lump, polyp, or mole.
• the procedure may involve the removal of larger amounts of tissue, such as breast, bone, skin, fat, or muscle.
• the procedure may involve removal of part of or the entirety of, an organ or node, for example, lung, throat, tongue, bladder, cervix, ovary, testicle, lymph node, liver, pancreas, brain, eye, kidney, gallbladder, stomach, colon, rectum, or intestine.
• the cancer is breast cancer, e.g., triple negative breast cancer
• the surgery is a mastectomy or lumpectomy.
• Antiinflammatory agents can include, but are not limited to, non-steroidal anti-inflammatory' agents (e.g., Salicylates (Aspirin (acetylsalicylic acid), Diflunisal, Salsalate), Propionic acid derivatives (Ibuprofen, Naproxen, Fenoprofen, Ketoprofen, Flurbiprofen, Oxaprozin, Loxoprofen), Acetic acid derivatives (Indomethacin, Sulindac, Etodolac, Ketorolac, Diclofenac, Nabumetone), Enolic acid (Oxicam) derivatives (Piroxicam, Meloxicam, Tenoxicam, Droxicam, Lomoxicam, Isoxicam), Fenamic acid derivatives ( Fenamates )(Mefenamic acid, Meclofenamic acid, Flufenamic acid.
• non-steroidal anti-inflammatory' agents e.g., Salicylates (Aspirin
• COX -2 inhibitors Coxibs
• Ceiecoxib Ceiecoxib
• Sulphon anilides Niimesulide
• Steriods e.g. Hydrocortisone (Cortisol), Cortisone acetate, Prednisone, Prednisolone, Methylprednisolone, Dexamethasone, Betamethasone, Triamcinolone, Beclometasone, Fludrocortisone acetate. Deoxycorticosterone acetate, Aldosterone).
• Analgesics can include but are not limited to, opiates (e.g. morphine, codeine, oxycodone, hydrocodone, dihydromorphine, pethidine, buprenorphine, tramadol, venlafaxine), paracetomal and Nonsteroidal anti-inflammatory' agents (e.g., Salicylates (Aspirin (acetylsalicylic acid), Diflunisal, Salsalate), Propionic acid derivatives (Ibuprofen, Naproxen, Fenoprofen, Ketoprofen, Flurbiprofen, Oxaprozin, Loxoprofen), Acetic acid derivatives (Indomethacin, Sulindac, Etodolac, Ketorolac, Diclofenac, Nabumetone), Enolic acid (Oxicam) derivatives (Piroxicam, Meloxicam, Tenoxicam, Droxicam, Lomoxicam, Isoxicam), Fenamic
• Antiemetic agents can include, but are not limited to, 5-HT3 receptor antagonists (Dolasetron (Anzemet), Granisetron (Kytril, Sancuso), Ondansetron (Zofran), Tropisetron (Navoban), Palonosetron (Aloxi), Mirtazapine (Remeron)), Dopamine antagonists (Domperidone, Olanzapine, Droperidol, Haloperidol, Chlorpromazine, Promethazine, Prochlorperazine, Metoclopramide (Reglan), Alizapride, Prochlorperazine (Compazine, Stemzine, Buccastem, Stemet.il, Phenotil), NK1 receptor antagonist (Aprepitant (Emend), Antihistamines (Cyclizine, Diphenhydramine (Benadryl), Dimenhydrinate (Gravol, Dramamine), Meclozine (Bonine, Antivert
• phrases, "in combination with,” and the terms "co-administration,” “coadministering,” or “co-providing”, as used herein in the context of the administration of a compound described herein or a therapy described herein, means that two (or more) different compounds or therapies are delivered to the subject during the course of the subject's affliction with the disease or disorder (e.g., a disease or disorder as described herein, e.g., cancer), e.g., two (or more) different compounds or therapies are delivered to the subject after the subject has been diagnosed with the disease or disorder (e.g., a disease or disorder as described herein, e.g., cancer) and before the disease or disorder has been cured or eliminated or treatment has ceased for other reasons.
• the disease or disorder e.g., a disease or disorder as described herein, e.g., cancer
• the delivery of one compound or therapy is still occurring when the delivery of the second begins, so that there is overlap in terms of administration. This is sometimes referred to herein as “simultaneous" or “concurrent delivery.”
• the delivery' of one compound or therapy ends before the delivery' of the other compound or therapy begins.
• the treatment e.g., administration of compound, composition, or therapy
• the treatment is more effective because of combined administration.
• the second compound or therapy is more effective, e.g., an equivalent effect is seen with less of the second compound or therapy, or the second compound or therapy reduces symptoms to a greater extent, than would be seen if the second compound or therapy were administered in the absence of the first compound or therapy, or the analogous situation is seen with the first compound or therapy.
• delivery' is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one compound or therapy delivered in the absence of the other.
• the effect of the two compounds or therapies can be partially additive, wholly additive, or greater than additive (e.g., synergistic).
• the delivery can be such that the first compound or therapy delivered is still detectable when the second is delivered.
• the first compound or therapy and second compound or therapy can be administered simultaneously (e.g., at the same time), in the same or in separate compositions, or sequentially.
• Sequential administration refers to administration of one compound or therapy before (e.g., immediately before, less than 5, 10, 15, 30, 45, 60 minutes; 1 , 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 48, 72, 96 or more hours; 4, 5, 6, 7, 8, 9 or more days; 1 , 2, 3, 4, 5, 6, 7, 8 or more weeks before) administration of an additional, e.g., secondary', compound or therapy.
• the order of administration of the first and secondary compound or therapy can also be reversed.
• the combinations described herein can be a first line treatment for abnormal cell growth, e.g., cancer, i.e., it is used in a patient who has not been previously administered another drug intended to treat the cancer; a second line treatment for the cancer, i.e., it is used in a subject in need thereof who has been previously administered another drug intended to treat the cancer; a third or fourth treatment for the cancer, i.e., it is used in a subject who has been previously administered two or three other drags intended to treat the cancer.
• a first line treatment for abnormal cell growth e.g., cancer
• a second line treatment for the cancer i.e., it is used in a subject in need thereof who has been previously administered another drug intended to treat the cancer
• a third or fourth treatment for the cancer i.e., it is used in a subject who has been previously administered two or three other drags intended to treat the cancer.
• synergy scores may be calculated using a combination of 4 different methods (Bliss, Loewe, HSA and ZIP).
• the SHP2 inhibitor, the S0S1 inhibitor, the ERK1/2 inhibitor, the CDK4/6 inhibitor, the AKT inhibitor, the mTOR inhibitor, the pan-HER inhibitor, or the EGFR inhibitor and the MEK inhibitor are administered at amounts (e.g., doses) that result in a synergistic (e.g., therapeutic) effect.
• the SHP2 inhibitor, the S0S1 inhibitor, the ERK1/2 inhibitor, the CDK4/6 inhibitor, the AKT inhibitor, the mTOR inhibitor, the pan-HER inhibitor, or the EGFR inhibitor and the dual RAF/MEK inhibitor are administered at amounts (e.g., doses) that result in a synergistic (e.g., therapeutic) effect.
• the combinations of this invention may be administered orally, parenterally, topically, rectally, or via an implanted reservoir, preferably by oral administration or administration by injection.
• the pH of the composition e.g., pharmaceutical composition
• the pH of the composition may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability or efficacy of the composition.
• the subject is administered the composition (e.g., pharmaceutical composition) orally.
• the composition e.g., pharmaceutical composition
• Liqui-gels may include gelatins, plasticisers, and/or opacifiers, as needed to achieve a suitable consistency and may be coated with enteric coatings that are approved for use, e.g., shellacs. Additional thickening agents, for example gums, e.g., xanthum gum, starches, e.g., corn starch, or glutens may be added to achieve a desired consistency of the composition (e.g., pharmaceutical composition) when used as an oral dosage. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
• enteric coatings that are approved for use, e.g., shellacs.
• Additional thickening agents for example gums, e.g., xanthum gum, starches, e.g., corn starch, or glutens may be added to achieve a desired consistency of the composition (e.g., pharmaceutical composition) when used as an oral dosage. If desired, certain sweetening and/or flavoring and/or coloring agents
• the subject is administered the composition (e.g., pharmaceutical composition) in a form suitable for oral administration such as a tablet, capsule, pill, powder, sustained release formulations, solution, and suspension.
• the composition e.g., pharmaceutical composition
• the composition may be in unit dosage forms suitable for single administration of precise dosages.
• Pharmaceutical compositions may comprise, in addition to a compound as described herein a pharmaceutically acceptable carrier, and may optionally further comprise one or more pharmaceutically acceptable excipients, such as, for example, stabilizers, diluents, binders, and lubricants.
• the tablet may include other medicinal or pharmaceutical agents, carriers, and or adjuvants.
• Exemplary' pharmaceutical compositions include compressed tablets (e.g., directly compressed tablets).
• Tablets are also provided comprising the active or therapeutic ingredient (e.g., compound as described herein).
• tablets may contain a number of inert materials such as earners.
• Pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, sesame oil and the like. Saline solutions and aqueous dextrose can also be employed as liquid earners.
• Oral dosage forms for use in accordance with the present invention thus may be formulated in conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Excipients can impart good powder flow and compression characteristics to the material being compressed.
• the active ingredients e.g., the compound as described herein can be formulated readily by combining the active ingredients with pharmaceutically acceptable carriers well known in the art.
• Such carriers enable the active ingredients of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, powders or granules, suspensions or solutions in water or non-aqueous media, and the like, for oral ingestion by a subject.
• Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain, for example, tablets.
• suitable excipients such as diluents, binders or disintegrants may be desirable.
• the dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in ' he Pharmacological Basis of Therapeutics"). Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular subject will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the subject's di sposition to the disease, condition or symptoms, and the judgment of the treating phy sician.
• a course of therapy can comprise one or more separate administrations of a compound as described herein.
• a course of therapy can comprise one or more cycles of a compound as described herein.
• a cycle refers to a period of time for which a drug is administered to a patient.
• the periodic administration e.g., daily or twice daily
• a drag can be administered for more than one cycle.
• Rest periods may be interposed between cycles.
• a rest cycle may be 1, 2, 4, 6, 8, 10, 12, 16, 20, 24 hours, 1 , 2, 3, 4, 5, 6, 7 days, or 1 , 2, 3, 4 or more weeks in length.
• Oral dosage forms may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient.
• the pack may, for example, comprise metal or plastic foil, such as a blister pack.
• the pack or dispenser device may be accompanied by instructions for administration.
• the pack or dispenser may also be accompanied by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration.
• Such notice for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.
• the methods provided herein also encompass methods for screening or identifying subjects having a cancer suitable for treatment with a MEK inhibitor or a dual RAF/MEK inhibitor in combination with a SHP2 inhibitor.
• the methods contemplate identifying a subject who is likely to be responsive to a treatment of a cancer described herein.
• methods for optimizing therapeutic efficacy for treatment of a subject having a cancer wherein the treatment comprises administering a MEK inhibitor or a dual RAF/MEK inhibitor in combination with a SHP2 inhibitor.
• a method of detecting presence of a SHP2 gene mutation associated with a subject having a cancer comprising:
• a method of identifying a subject having a cancer with a SHP2 gene mutation comprising:
• provided herein are methods for screening or identifying subjects having a cancer suitable for treatment with a MEK inhibitor or a dual RAF/MEK inhibitor in combination with a S0S1 inhibitor.
• the methods contemplate identifying a subject who is likely to be responsive to a treatment of a cancer described herein.
• methods for optimizing therapeutic efficacy for treatment of a subject having a cancer wherein the treatment comprises administering a MEK inhibitor or a dual RAF/MEK inhibitor in combination with a S0S1 inhibitor.
• a method of detecting presence of a S0S1 gene mutation associated with a subject having a cancer comprising:
• a method of identifying a subject having a cancer with a S0S1 gene mutation comprising: (a) obtaining a biological sample from the subject; and
• provided herein are methods for screening or identifying subjects having a cancer suitable for treatment with a MEK inhibitor or a dual RAF/MEK inhibitor in combination with a ERK1/2 inhibitor.
• the methods contemplate identifying a subject who is likely to be responsive to a treatment of a cancer described herein.
• methods for optimizing therapeutic efficacy for treatment of a subject having a cancer wherein the treatment comprises administering a MEK inhibitor or a dual RAF/MEK inhibitor in combination with a ERK1/2 inhibitor.
• a method of detecting presence of a ERK1/2 gene mutation associated with a subject having a cancer comprising:
• a method of identifying a subject having a cancer with a ERK1/2 gene mutation comprising:
• provided herein are methods for screening or identifying subjects having a cancer suitable for treatment with a MEK inhibitor or a dual RAF/MEK inhibitor in combination with a CDK4/6 inhibitor.
• the methods contemplate identifying a subject who is likely to be responsive to a treatment of a cancer described herein.
• methods for optimizing therapeutic efficacy for treatment of a subject having a cancer wherein the treatment comprises administering a MEK inhibitor or a dual RAF/MEK inhibitor in combination with a CDK4/6 inhibitor.
• a method of detecting presence of a CDK4/6 gene mutation associated with a subject having a cancer comprising:
• a method of identifying a subject having a cancer with a CDK4/6 gene mutation comprising:
• provided herein are methods for screening or identifying subjects having a cancer suitable for treatment with a MEK inhibitor or a dual RAF/MEK inhibitor in combination with an AKT inhibitor.
• the methods contemplate identifying a subject who is likely to be responsive to a treatment of a cancer described herein.
• methods for optimizing therapeutic efficacy for treatment of a subject having a cancer wherein the treatment comprises administering a MEK inhibitor or a dual RAF/MEK inhibitor in combination with an AKT inhibitor.
• a method of detecting presence of an AKT gene mutation associated with a subject having a cancer comprising:
• a method of identifying a subject having a cancer with a AKT gene mutation comprising:
• provided herein are methods for screening or identifying subjects having a cancer suitable for treatment with a MEK inhibitor or a dual RAF/MEK inhibitor in combination with an mTOR inhibitor.
• the methods contemplate identifying a subject who is likely to be responsive to a treatment of a cancer described herein.
• methods for optimizing therapeutic efficacy for treatment of a subject having a cancer wherein the treatment comprises administering a MEK inhibitor or a dual RAF/MEK inhibitor in combination with an mTOR inhibitor.
• a method of detecting presence of an mTOR gene mutation associated with a subject having a cancer comprising:
• a method of identifying a subject having a cancer with a mTOR gene mutation comprising:
• provided herein are methods for screening or identifying subjects having a cancer suitable for treatment with a MEK inhibitor or a dual RAF/MEK inhibitor in combination with a pan-HER inhibitor.
• the methods contemplate identifying a subject who is likely to be responsive to a treatment of a cancer described herein.
• methods for optimizing therapeutic efficacy for treatment of a subject having a cancer wherein the treatment comprises administering a MEK inhibitor or a dual RAF/MEK inhibitor in combination with a pan-HER inhibitor.
• a pan-HER gene mutation associated with a subject having a cancer comprising:
• a method of identifying a subject having a cancer with a pan-HER gene mutation comprising:
• provided herein are methods for screening or identifying subjects having a cancer suitable for treatment with a MEK inhibitor or a dual RAF/MEK inhibitor in combination with a EGFR inhibitor.
• the methods contemplate identifying a subject who is likely to be responsive to a treatment of a cancer described herein.
• methods for optimizing therapeutic efficacy for treatment of a subject having a cancer wherein the treatment comprises administering a MEK inhibitor or a dual RAF/MEK inhibitor in combination with a EGFR inhibitor.
• a method of detecting presence of a EGFR gene alteration associated with a subject having a cancer comprising:
• a method of identifying a subject having a cancer with a EGFR gene alteration comprising:
• Samples include, but are not limited to, tissue samples (e.g., tumor tissue samples), primary or cultured cells or cell lines, cell supernatants, cell lysates, platelets, serum, plasma, vitreous fluid, lymph fluid, synovial fluid, follicular fluid, seminal fluid, amniotic fluid, milk, whole blood, blood-derived cells, urine, cerebro-spinal fluid, saliva, sputum, tears, perspiration, mucus, tumor lysates, and tissue culture medium, tissue extracts such as homogenized tissue, tumor tissue, cellular extracts, and combinations thereof.
• the sample is serum, blood, urine, or plasma.
• Identification of the particular mutational status of the SHP2, S0S1, ERK1/2, CDK4/6, AKT, mTOR, pan-HER, or EGFR gene in a sample obtained from the individual may be performed by any of a number of methods well known to one of skill in the art.
• identification of the mutation can be accomplished by cloning of the SHP2, S0S1, ERK1/2, CDK4/6, AKT, mTOR, pan-HER, or EGFR gene, or portion thereof, and sequencing it using techniques well known in the art.
• the gene sequences can be amplified from genomic DNA, e.g. using PCR, and the product sequenced.
• the assay comprises sequencing.
• the assay comprises polymerase chain reaction (PCR).
• PCR polymerase chain reaction
• Exemplary assay includes, but is not limited to, nucleic acid sequencing (dideoxy and pyrosequencing), real-time PCR with melt-curve analysis, and allele-specific PCR with various modes used to distinguish mutant from wild-type sequences.
• Assay may also include quantitatively or semi -quantitatively determining the amount of the mutation in cell free DNA (cfDNA) in the sample.
• KRAS G12C, G12D or G12V mutant non-small cell lung cancer (NSCLC) and pancreatic cancer cell lines were grown in 3D conditions. Briefly, 96-well plates were coated with 50 pL of Matrigel (100%) and incubated at 37°C and 5% CO2 for 30 min in order for the Matrigel to solidify. Cells were seeded in 100 pL of 2% Matrigel containing medium. After an incubate overnight (17-22 hours) cells were treated with VS-6766 +/- SHP2i (TNO155 or RMC-4550) for 7 days. Cell viability was measured using the cell viability CellTiter-Glo assay. FIG.
• 1A shows exemplary CellTiter-Glo assay to evaluate cell viability on a 16 KRAS G12C, G12D or G12V mutant cell lines (9 NSCLC and 7 PDAC) grown in 3D conditions in a 7-day assay.
• IC50 for VS-6766, TNO155 and RMC-4550 were calculated (FIG. IB). Synergy analysis.
• FIG. 2A shows cells were run in a CTG proliferation assay.
• Raw data and metadata files were processed with a custom R-script for single agent and combination activity.
• Bliss, Loewe, Highest Single Agent (HSA) and ZIP synergy analysis were performed to generate a composite synergy score.
• FIG. 2A shows cells were run in a CTG proliferation assay.
• Raw data and metadata files were processed with a custom R-script for single agent and combination activity.
• Bliss, Loewe, Highest Single Agent (HSA) and ZIP synergy analysis were performed to generate a composite synergy score.
• FIG. 2B shows an example for VS-6766 + TNO155 in H2122 cells.
• FIG. 2C shows waterfall graphs that summarize the combination synergy results for VS-6766 + TNO155 in a panel of KRAS mut NSCLC and PDAC cell lines.
• Tumor sizes (mm 3 ) and body weights were measured 2 times per week for the duration of the study. At the time of routine monitoring, the animals were checked for any effects of tumor growth and treatments on normal behavior such as mobility, food and water consumption (by looking only), and body weight gain/loss, eye/hair matting and any other abnormal effect.
• Dose-response matrices were used to assess anti -proliferative effects of the combination of VS- 6766 and TNO155 or RMC-4550. Synergy scores were calculated using a combination of 4 different methods (Bliss, Loewe, HSA and ZIP). VS-6766 was synergistic with TNO155 (FIG. 3A, FIG. 3B) or RMC-4550 (FIG. 4A, FIG. 4B) in reducing viability of a panel of 16 KRAS mutant (G12C, G12D and G12V) NSCLC and pancreatic cancer cell lines.
• FIG. 5A We also investigated whether VS-6766 augments the efficacy of the SHP2 inhibitor RMC- 4550 in the KRAS mutant H2122 NSCLC model in vivo. It was found that the combination of VS-6766 + RMC-4550 increased tumor growth inhibition compared to either single agent alone.
• FIG. 5B We next investigated whether VS-6766 augments the efficacy of the SHP2 inhibitor TNO155 in the KRAS mutant H2122 NSCLC model in vivo. It was found that the combination of VS-6766 + TNO155 increased tumor growth inhibition compared to either single agent alone.
• KRAS G12C, G12D or G12V mutant non-small cell lung cancer (NSCLC) and pancreatic cancer cell lines were grown in 3D conditions. Briefly, 96-well plates were coated with 50 pL of Matrigel (100%) and incubated at 37°C and 5% CO2 for 30 min in order for the Matrigel to solidify. Cells were seeded in 100 pL of 2% Matrigel containing medium. After an incubate overnight (17-22 hours) cells were treated with VS-6766 +/- BI-3406 for 7 days. Cell viability was measured using the cell viability CellTiter-Glo assay. FIG.
• 6A shows exemplary CellTiter- Glo assay to evaluate cell viability on a 16 KRAS G12C, G12D or G12V mutant cell lines (9 NSCLC and 7 PDAC) grown in 3D conditions in a 7-day assay.
• IC50 for VS-6766 and BI- 3406 were calculated (FIG. 56).
• Raw data and metadata files were processed with a custom R-script for single agent and combination activity.
• Bliss, Loewe, Highest Single Agent (HSA) and ZIP synergy analysis were performed to generate a composite synergy score.
• Summary graphics and reports were saved for visualization and further analysis. Waterfall graphs were used to summarize the combination synergy results for VS-6766 + BI3406 .
• cells were run in a CTG proliferation assay (FIG. 7A).
• Raw data and metadata files were processed with a custom R- script for single agent and combination activity.
• Bliss, Loewe, Highest Single Agent (HSA) and ZIP synergy analysis were performed to generate a composite synergy score. Summary graphics and reports were saved for visualization and further analysis.
• FIG. 7B The example used in this figure is VS-6766 + BI-3406 in H2122 cells.
• Waterfall graphs summarize the combination synergy results for VS-6766 + BI-3406 in a panel of KRAS mut NSCLC and PDAC cell lines (FIG. 7C).
• Tumor sizes (mm 3 ) and body weights were measured 2 times per week for the duration of the study. At the time of routine monitoring, the animals were checked for any effects of tumor growth and treatments on normal behavior such as mobility, food and water consumption (by looking only), and body weight gain/loss, eye/hair matting and any other abnormal effect.
• Dose-response matrices were used to assess anti -proliferative effects of the combination of VS- 6766 and BI3406. Synergy scores were calculated using a combination of 4 different methods (Bliss, Loewe, HSA and ZIP). VS-6766 was synergistic with BI3406 in reducing viability of a panel of 16 KRAS mutant (G12C, G12D and G12V) NSCLC and pancreatic cancer cell lines.
• FIG. 8A shows an exemplary waterfall graph summarizing the combination synergy results for VS-6766 + BI3406 in a panel of KRAS mut NSCLC and PDAC cell lines. As example, the combination of VS-6766 with BI3406 increases anti-tumor responses in H2122 cells (FIG. 8B)
• KRAS G12C, G12D or G12V mutant non-small cell lung cancer (NSCLC) and pancreatic cancer cell lines were grown in 3D conditions. Briefly, 96-well plates were coated with 50 pL of Matrigel (100%) and incubated at 37°C and 5% CO2 for 30 min in order for the Matrigel to solidify. Cells were seeded in 100 pL of 2% Matrigel containing medium. After an incubate overnight (17-22 hours) cells were treated with VS-6766 +/- LY-3214996 for 7 days. Cell viability was measured using the cell viability CellTiter-Glo assay. FIG.
• FIG. 10A shows exemplary CellTiter-Glo assay to evaluate cell viability on a 16 KRAS G12C, G12D or G12V mutant cell lines (9 NSCLC and 7 PDAC) grown in 3D conditions in a 7-day assay.
• IC50 for VS-6766 and LY-3214996 were calculated (FIG. 10B).
• Raw data and metadata files were processed with a custom R-script for single agent and combination activity.
• Bliss, Loewe, Highest Single Agent (HSA) and ZIP synergy analysis were performed to generate a composite synergy score.
• Summary graphics and reports were saved for visualization and further analysis. Waterfall graphs were used to summarize the combination synergy results for VS-6766 + LY-3214996. In brief, cells were run in a CTG proliferation assay (FIG. 11 A).
• Raw data and metadata files were processed with a custom R- script for single agent and combination activity.
• Bliss, Loewe, Highest Single Agent (HSA) and ZIP synergy analysis were performed to generate a composite synergy score. Summary graphics and reports were saved for visualization and further analysis.
• FIG. 11B The example used in this figure is VS-6766 + LY-3214996 in H2122 cells.
• Waterfall graphs summarize the combination synergy results for VS-6766 + LY-3214996 in a panel of KRAS mut NSCLC and PDAC cell lines (FIG. 11C).
• Tumor sizes (mm 3 ) and body weights were measured 2 times per week for the duration of the study. At the time of routine monitoring, the animals were checked for any effects of tumor growth and treatments on normal behavior such as mobility, food and water consumption (by looking only), and body weight gain/loss, eye/hair matting and any other abnormal effect.
• Dose-response matrices were used to assess anti -proliferative effects of the combination of VS- 6766 and LY-3214996. Synergy scores were calculated using a combination of 4 different methods (Bliss, Loewe, HSA and ZIP). VS-6766 was synergistic with LY-3214996 in reducing viability of a panel of 16 KRAS mutant (G12C, G12D and G12V) NSCLC and pancreatic cancer cell lines.
• FIG. 12A shows an exemplary waterfall graph summarizing the combination synergy results for VS-6766 + LY-3214996 in a panel of KRAS mut NSCLC and PDAC cell lines. As example, the combination of VS-6766 with LY-3214966 increases anti-tumor responses in H2122 cells (FIG. 12B).
• KRAS G12C, G12D or G12V mutant non-small cell lung cancer (NSCLC) and pancreatic cancer cell lines were grown in 3D conditions.
• ER+ breast cancer cell lines were grown in 3D conditions. Briefly, 96-well plates were coated with 50 pL of Matrigel (100%) and incubated at 37°C and 5% CO2 for 30 min in order for the Matrigel to solidify. Cells were seeded in 100 pL of 2% Matrigel containing medium. After an incubate overnight (17-22 hours) cells were treated with VS-6766 +/- palbociclib or abemaciclib for 7 days. Cell viability was measured using the cell viability CellTiter-Glo assay.
• FIG. 14A shows an exemplary CellTiter-Glo assay to evaluate cell viability on a 16 KRAS G12C, G12D or G12V mutant cell lines (9 NSCLC and 7 PDAC) grown in 3D conditions in a 7-day assay.
• IC50 for VS-6766, palbociclib or abemaciclib were calculated (FIG. 14B). Synergy analysis.
• Raw data and metadata files were processed with a custom R-script for single agent and combination activity.
• Bliss, Loewe, Highest Single Agent (HSA) and ZIP synergy analysis were performed to generate a composite synergy score.
• Summary graphics and reports were saved for visualization and further analysis.
• Waterfall graphs were used to summarize the combination synergy results for VS-6766 + palbociclib or abemaciclib.
• cells were run in a CTG proliferation assay (FIG. 15A).
• Raw data and metadata files were processed with a custom R-script for single agent and combination activity.
• Bliss, Loewe, Highest Single Agent (HSA) and ZIP synergy analysis were performed to generate a composite synergy score.
• Tumor sizes (mm 3 ) and body weights were measured 2 times per week for the duration of the study. At the time of routine monitoring, the animals were checked for any effects of tumor growth and treatments on normal behavior such as mobility, food and water consumption (by looking only), and body weight gain/loss, eye/hair matting and any other abnormal effect.
• Dose-response matrices were used to assess anti -proliferative effects of the combination of VS- 6766 + palbociclib or abemaciclib. Synergy scores were calculated using a combination of 4 different methods (Bliss, Loewe, HSA and ZIP). VS-6766 was synergistic with palbociclib (FIG. 16A, FIG. 16B) or abemaciblib (FIG. 17A, FIG. 17B) in reducing viability of a panel of 16 KRAS mutant (G12C, G12D and G12V) NSCLC and pancreatic cancer cell lines.
• FIG. 19A shows that Bliss, Loewe, HSA and ZIP synergy analysis were performed to generate a combined synergy score.
• VS-6766 was synergistic with abemaciblib in reducing viability of a panel of 3 ER+ breast cancer cell lines.
• FIG. 19B shows the Bliss synergy scores in MCF7 ER+ breast cancer cell lines
• FIG. 19C shows the Bliss synergy scores in ZR-75-1 ER+ breast cancer cell lines.
• KRAS G12C, G12D or G12V mutant non-small cell lung cancer (NSCLC) and pancreatic cancer cell lines were grown in 3D conditions. Briefly, 96-well plates were coated with 50 pL of Matrigel (100%) and incubated at 37°C and 5% CO2 for 30 min in order for the Matrigel to solidify. Cells were seeded in 100 pL of 2% Matrigel containing medium. After an incubate overnight (17-22 hours) cells were treated with VS-6766 +/- ipatasertib, M2698 or everolimus for 7 days. Cell viability was measured using the cell viability CellTiter-Glo assay.
• Raw data and metadata files were processed with a custom R-script for single agent and combination activity.
• Bliss, Loewe, Highest Single Agent (HSA) and ZIP synergy analysis were performed to generate a composite synergy score.
• Summary graphics and reports were saved for visualization and further analysis.
• Waterfall graphs were used to summarize the combination synergy results for VS-6766 + ipatasertib, M2698 or everolimus.
• cells were run in a CTG proliferation assay (FIG. 21A).
• Raw data and metadata files were processed with a custom R-script for single agent and combination activity.
• Bliss, Loewe, Highest Single Agent (HSA) and ZIP synergy analysis were performed to generate a composite synergy score.
• Dose-response matrices were used to assess anti-proliferative effects of the combination of VS- 6766 + ipatasertib, M2698 or everolimus. Synergy scores were calculated using a combination of 4 different methods (Bliss, Loewe, HSA and ZIP). VS-6766 was synergistic with ipatasertib (FIG. 22A, FIG. 22B), M2698 (FIG. 23A, FIG. 23B) or everolimus (FIG. 24A, FIG. 24B) in reducing viability of a panel of 16 KRAS mutant (G12C, G12D and G12V) NSCLC and pancreatic cancer cell lines.
• KRAS G12C, G12D or G12V mutant non-small cell lung cancer (NSCLC) and pancreatic cancer cell lines were grown in 3D conditions. Briefly, 96-well plates were coated with 50 pL of Matrigel (100%) and incubated at 37°C and 5% CO2 for 30 min in order for the Matrigel to solidify. Cells were seeded in 100 pL of 2% Matrigel containing medium. After an incubate overnight (17-22 hours) cells were treated with VS-6766 +/- afatinib for 7 days. Cell viability was measured using the cell viability CellTiter-Glo assay.
• Raw data and metadata files were processed with a custom R-script for single agent and combination activity.
• Bliss, Loewe, Highest Single Agent (HSA) and ZIP synergy analysis were performed to generate a composite synergy score.
• Summary graphics and reports were saved for visualization and further analysis. Waterfall graphs were used to summarize the combination synergy results for VS-6766 + afatinib. In brief, cells were run in a CTG proliferation assay (FIG. 26A).
• Raw data and metadata files were processed with a custom R- script for single agent and combination activity.
• Bliss, Loewe, Highest Single Agent (HSA) and ZIP synergy analysis were performed to generate a composite synergy score. Summary graphics and reports were saved for visualization and further analysis.
• FIG. 26B The example used in this figure is VS-6766 + afatinib in H2122 cells.
• Waterfall graphs summarize the combination synergy results for VS-6766 + afatainib in a panel of KRAS mut NSCLC and PDAC cell lines (FIG. 26C).
• Tumor sizes (mm 3 ) and body weights were measured 2 times per week for the duration of the study. At the time of routine monitoring, the animals were checked for any effects of tumor growth and treatments on normal behavior such as mobility, food and water consumption (by looking only), and body weight gain/loss, eye/hair matting and any other abnormal effect. Results
• Dose-response matrices were used to assess anti -proliferative effects of the combination of VS- 6766 and afatinib. Synergy scores were calculated using a combination of 4 different methods (Bliss, Loewe, HSA and ZIP). VS-6766 was synergistic with afatinib in reducing viability of a panel of 16 KRAS mutant (G12C, G12D and G12V) NSCLC and pancreatic cancer cell lines (FIG. 27A, FIG. 27B).
• the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim.
• any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim.
• elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements and/or features, certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements and/or features.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• Organic Chemistry (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Physics & Mathematics (AREA)
• Biotechnology (AREA)
• Biochemistry (AREA)
• Microbiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Analytical Chemistry (AREA)
• General Physics & Mathematics (AREA)
• Zoology (AREA)
• Cell Biology (AREA)
• Toxicology (AREA)
• Pathology (AREA)
• Food Science & Technology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Tropical Medicine & Parasitology (AREA)
• Wood Science & Technology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (10)

Applications Claiming Priority (20)

Publications (1)

Family

ID=82741881

Family Applications (1)

Country Status (10)

Cited By (10)

Families Citing this family (1)

Citations (3)

Family Cites Families (3)

• 2022
  • 2022-02-04 JP JP2023547408A patent/JP2024505680A/ja active Pending
  • 2022-02-04 KR KR1020237029729A patent/KR20230142757A/ko active Pending
  • 2022-02-04 WO PCT/US2022/015262 patent/WO2022170060A1/en not_active Ceased
  • 2022-02-04 AU AU2022216284A patent/AU2022216284A1/en not_active Abandoned
  • 2022-02-04 EP EP22750444.6A patent/EP4288057A4/en active Pending
  • 2022-02-04 BR BR112023015616A patent/BR112023015616A2/pt unknown
  • 2022-02-04 CA CA3210506A patent/CA3210506A1/en active Pending
  • 2022-02-04 MX MX2023009223A patent/MX2023009223A/es unknown
  • 2022-02-04 IL IL304908A patent/IL304908A/en unknown
  • 2022-02-04 US US18/263,820 patent/US20240115571A1/en active Pending

Patent Citations (3)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events